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Abstract 
B cell Acute Lymphoblastic Leukemia (B-ALL) arises from transformation of 
progenitor B cells1.  The transcription factor STAT5 plays a critical role in B-ALL, as high 
STAT5 activation is correlated with poor patient survival2.  How STAT5 mediates this 
effect is unclear.  Previous studies suggested that STAT5 simply promotes the survival 
of progenitor B cells3,4.  However, other roles for STAT5 in B-ALL have not been 
explored.  This study demonstrates that STAT5 activation drives leukemia in cooperation 
with defects in a linear signaling pathway emanating from the pre-BCR, including Blnk, 
Btk, Prkcb, Nfkb1, and Ikaros.  Using microarray analysis and chromatin 
immunoprecipitation followed by high throughput sequencing (ChIP-seq), we 
demonstrate that STAT5 antagonizes NFκB and IKAROS by opposing regulation of 
shared target genes.  High levels of STAT5 binding was enriched at super-enhancers 
that are typically associated with an opposing network of B cell transcription factors 
including PAX5, EBF1, PU.1, IRF4, or IKAROS.  The antagonism between STAT5 and 
NFκB or IKAROS has direct clinical relevance as the balance between these 
transcription factors affects patient outcome.  Patients with high ratios of active STAT5 to 
NFκB or IKAROS have more aggressive disease characterized by decreased survival.   
Our studies illustrate how modest perturbations in two opposing transcriptional programs 
have dramatic consequences for B cell transformation, and that the degree of 
antagonism between these transcriptional programs correlates with patient survival.   
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Chapter 1:  A network of B cell transcription factors, STAT5, and pre-BCR 
signaling regulate the development and transformation of B cell progenitors 
Introduction  
 Acute Lymphoblastic Leukemia (ALL) arises from the transformation of B or T 
cell progenitors.  An estimated 6,000 new cases of ALL are diagnosed each year in the 
United States5.  Roughly 60% of those cases occur in adolescents5, making ALL the 
most common cancer in children6.  With the advent of new therapies, the 5-year event 
free survival of children with ALL has improved from less than 10% in the 1960s7 to 80-
90% today5,8.  While this is a great improvement, ALL remains the leading cause of 
cancer-related death in children and young adults5,9. 
Current treatments for ALL typically involve a cocktail of four drugs that non-
specifically target leukemic cells by inhibiting mitosis, DNA replication, inflammation, and 
the availability of L-aspargine10,11.  Consequently, more than two-thirds of the children 
that survive longer than 5 years from diagnosis suffer from treatment-related side effects 
such as: impaired intellectual and psychomotor functioning, neuroendocrine 
abnormalities, impaired reproductive capacity, cardiotoxicity, and second malignant 
neoplasms12,13.  Thus, current therapies are non-specific, leading to many off-target 
effects that can reduce the quality of life for survivors14.  Therefore, there is a need for 
new therapies that specifically target ALL and cause minimal side effects. 
The outcome for adults with ALL tends to be much worse, as only 30% of adults 
achieve long-term disease free survival15.  The poorer prognosis has been attributed to 
an increased frequency of high-risk leukemia subtypes, poorer tolerance of treatment, 
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and less effective treatment regimens compared to childhood ALL12.  Risk factors for 
ALL include: age, sex, white blood cell count at diagnosis, cytogenetics, and the level of 
minimal residual disease6,9.  However, these factors are unable to accurately predict all 
patients who go on to relapse6.  Moreover, some patient subgroups that currently receive 
intensive therapy are likely being over-treated16.  These patients could potentially be 
cured using less intensive regimens, resulting in reduced toxicity and fewer long-term 
side effects16.  Therefore, new stratification methods need to be developed to more 
accurately identify patients that are most likely to relapse.  Such stratification methods 
could be used to develop more personalized therapies.  For example, those high-risk 
patients could then be treated more aggressively than low-risk patients.  This should 
reduce the number of patients that are being over treated by therapeutic regimens.  To 
reiterate, current therapies are insufficient and a next generation of ALL therapies needs 
to be developed to more specifically and effectively treat ALL.  In order to develop such 
therapies, we need to better understand the underling mechanisms that drive the 
development of ALL, particularly those within high-risk patient groups that are less likely 
to respond to current therapies. 
The vast majority of ALL cases (85%) result from the transformation of one or 
more B cell progenitors (B-ALL)17.  B-ALL is characterized as a block in B cell 
differentiation, leading to an accumulation of progenitor B cells in the bone marrow, 
blood, and occasionally the central nervous system17.  The stage at which this block 
occurs varies; however, most B-ALL cases exhibit a pre-B cell phenotype18.  Mutations 
that only cause a block in B cell development usually are not sufficient to cause 
disease19–25.  Consequently, transformed B cell progenitors accumulate other critical 
genetic lesions that drive leukemogenesis26.  Genes that are frequently mutated in B-
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ALL cases typically control the survival, proliferation, and differentiation of B cell 
progenitors during normal B cell development26–29. 
B lymphopoiesis 
The stages of B cell development 
In adults, B cell development begins solely in the bone marrow.  The earliest B 
cell progenitors in the bone marrow are hematopoietic stem cells (HSCs) (Figure 1.1).  
HSCs are pluripotent, as they can differentiate into any cell of the blood lineage:  
erythrocytes, megakaryocytes, basophils, eosinophils, neutrophils, macrophages, 
dendritic cells (DCs), NK cells, T cells, and B cells.  HSCs also have the capacity to self-
renew by dividing at a low rate, thus maintaining this population of cells.  The next stage 
of B cell differentiation is multipotent progenitors (MPPs).  MPPs can still mature into all 
hematopoietic linages, but have lost the ability to self-renew30.  MPPs can then give rise 
to lymphoid-primed multipotent progenitors (LMPPs), which have lost megakaryocyte 
and erythroid differentiation potential30.  LMPPs are heterogeneous and include cells that 
are biased toward one of several lineages, including B and T cells31.  The next B cell 
differentiation stage is the common lymphoid progenitor (CLP).  CLPs are more biased 
to the lymphoid compartment than LMPPs, as they can only mature into B cells, T cells, 
NK cells, and some DC subsets30.  CLPs that encounter the proper signals, such as the 
cytokine IL7, can differentiate into pre-pro-B cells30.  B cell progenitors then develop in a 
linear progression through several stages of differentiation: pre-pro-B to early pro-B to 
late pro-B to large pre-B to small pre-B to immature B and finally to mature B.  B cell 
progenitors are not fully committed to the B lineage until the pro-B cell stage32, at which 
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point no alternative lineage potential exists.  All stages take place in the bone marrow 
until the immature B cell stage.  Once generated, immature B cells migrate via the blood 
to the spleen, where they pass through the transitional 1 (T1) stage and then the T2 
stage of differentiation before maturing into mature B cells33. 
 
Pre-pro-BLMPP CLP
Early 
pro-B
Late 
pro-B
Large 
pre-B
Small 
pre-B Immature BHSC MPP Mature B
Megakaryocytes
Erythrocytes
Granulocytes T cells
NK cells
B-lineage
commitment
?
Ikaros-/-
E2a-/-
Irf8-/- Ebf1-/-
Ikaros-/-
Pu.1-/-
Ikaros-/-
Pax5-/-
Irf4/8-/-
IkarosΔ/Δ
Aiolos-/-
cRel-/-
Rela-/-
Nfkb1/2-/-
E2a-/-
Foxo1-/-
Stat5a/b-/-
pre-BCR BCR BCR
Bone marrow Spleen 	  
Figure 1.1. Disruption of the B cell transcriptional network blocks B cell 
development.   
B cell development begins in the bone marrow, where progenitor B cells pass through 
several stages of differentiation before migrating to the spleen to complete maturation.  
Cells are committed to the B-lineage at the early pro-B cell stage and potentially at the 
pre-pro-B cell stage.  The pre-BCR is expressed exclusively on large pre-B cells, where 
as the BCR is expressed on immature and mature B cells.  Loss of function mutations in 
key B cell transcription factors lead to blocks in B cell differentiation at various 
developmental stages19,34–53. 
 
Immunoglobulin recombination 
In order to be able to combat a wide variety of pathogens, B cells possess a very 
diverse antibody repertoire.  This diversity is generated by a process called 
immunoglobulin (Ig) recombination, which generates more potential antibodies (1011), 
than there are protein-coding genes (~2x105) in the human genome33,54.  To achieve this 
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feat, recombination shuffles the immunoglobulin gene segments to create unique 
combinations.   
Antibodies are composed of two heavy and two light chains, or immunoglobulins 
(Igs)33.  Each heavy chain (IgH) is composed of one variable (V) segment, one diversity 
(D) segment, one joining (J) segment, and one constant (C) segment33.  Each light chain 
also contains one V segment, one J segment, and one C segment, but no D segment33.  
The human heavy chain locus contains ~40 V (VH) segments, 23 D (DH) segments, 6 J 
(JH) segments, and 9 constant segments33.  The light chain can be encoded by the κ or λ 
loci33.  The κ locus is composed of 38 V (Vκ) segments, 5 J (Jκ) segments, and one C 
(Cκ) segment33.  Similarly, the λ locus is contains of 30 V (Vλ) segments, and 4 J (Jλ) 
segments33.  Each Jλ segment is linked to a single C (Cλ) segment, therefore there are 
4 Cλ segments in total33.  The organization of the immunoglobulin loci helps facilitate the 
recombination process33. 
Extensive mouse studies have revealed that recombination is executed by the 
recombinase complex33.  This complex is composed of the recombination-activating 
genes, RAG1 and RAG2, DNA-dependent protein kinase (DNA-PK), and the nuclease 
ARTEMIS33.  Each V, D, and J segment is flanked by DNA elements called 
recombination signal sequences (RSSs).  Recombination is initiated by the recognition 
of the RSSs by a complex of RAG1 and RAG2 (RAG1/2)33.  RAG1/2, in combination with 
DNA-PK and ARTEMIS, cut the DNA at two compatible RSSs, which are adjacent to 
each of the two Ig segments that are to be ligated together (one VH and one DH, for 
example)33.  Then, the enzyme terminal deoxynucleotidyl transferase (TdT or Dntt) adds 
random nucleotides to the ends of the cut, single-stranded DNA33.  These additional 
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nucleotides add further diversity to the antibody repertoire33.  DNA ligase IV and the 
recombinase complex then link these two DNA segments together33.  The RSSs are 
organized such that only one VH segment can recombine with one DH segment, which 
can then be linked to one JH segment33.  Moreover, VH cannot recombine to JH directly 
because of the orientation of the RSSs. This is similarly orchestrated in the light chain 
locus33.   
During B cell development, the heavy chain is rearranged first, followed by the 
light chain33.  The first heavy chain recombination events involve the joining of the DH 
and JH segments33.  This can occur in LMPPs, CLPs, pre-pro-B cells, or early pro-B 
cells33,55.  Then the VH to DJH segments are rearranged in late pro-B cells33.  This 
recombined µ heavy chain (µH) then pairs with an invariant, surrogate light chain on the 
cell surface33.  The surrogate light chain is composed of VPREB1 and λ5, which exhibit 
homology to a V segment and Cλ segment, respectively33.  The µ heavy chain and 
surrogate light chain pair with Igα and Igβ to form a pre-B cell receptor (pre-BCR)33.  
Cells that express the pre-BCR are termed large pre-B cells33.  Signaling through the 
pre-BCR acts as a checkpoint to test whether the cell has successfully recombined a 
heavy chain that can pair with a surrogate light chain33.  If recombination of the first 
heavy chain allele is unsuccessful, then the cell attempts to rearrange the second heavy 
chain allele33.  If progenitor B cells fail to produce a functional heavy chain a second 
time, then they die by apoptosis – at least 45% of pro-B cells are lost at this stage33.   
Functional pre-BCR signaling then stimulates the rearrangement of the light 
chain33.  Pre-B cells first attempt to rearrange the κ locus, then the λ locus33.  If 
successful, a κ or λ chain pairs with the µ heavy chain, generating a surface IgM 
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antibody33.  This IgM forms a complex with Igα and Igβ to form a B cell receptor (BCR)33.  
The first cells to express a BCR are immature B cells33.  Recombination is limited to one 
immunoglobulin allele at a time; thus, limiting the number of B cells that express multiple 
antibodies with different specificities33.  
In order to develop into mature B cells, B cell progenitors must rearrange a heavy 
chain that pairs with the surrogate light chain to form a pre-BCR33.  Pre-BCR signaling 
then initiates light chain recombination to generate a BCR33.  Therefore, evolution has 
generated a system that tests for the successful rearrangement of the heavy and light 
chains separately.  Consequently, B cell progenitors can sense whether an unsuccessful 
rearrangement is due to defects in the heavy or light chain and attempt to rearrange 
another allele of the same locus.  Ultimately, recombination generates a vast repertoire 
of immature B cells capable of recognizing many different antigens33. 
 
Negative and positive selection 
Once an immature B cell expresses a BCR, it is tested for reactivity to self-
antigens in the bone marrow33.  If an immature B cell is self-reactive (~75% are self-
reactive)56, then it has four potential fates: production of a new BCR (receptor editing), 
clonal deletion, anergy, or ignorance33.  If a BCR multivalently binds to a self-antigen, 
then the cell attempts to rearrange the other κ allele33.  If that is unsuccessful, then the 
cell tries to recombine the λ alleles33.  This process of receptor editing, gives the 
immature B cells another chance to express a BCR that is not self-reactive33.  If receptor 
editing is unsuccessful, then the cell dies by apoptosis in a process called clonal 
deletion33.  Multivalent binding tends to occur when the self-antigen is expressed on the 
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surface of a cell in the bone marrow33.  Immature B cells that encounter more weakly 
cross-linking self-antigens of low valence, such as small soluble proteins, are rendered 
anergic33.  Anergic B cells are unresponsive, as they cannot be activated by their 
antigen, even with CD4 T cell help33.  Finally, if an immature B cell has affinity for a self-
antigen, but does not respond to it, then it is considered ignorant33.  Ignorance can occur 
when the self-antigen is inaccessible to the immature B cell, is in low concentration, or 
binds weakly enough that it does not activate the B cell33.  These processes that 
eliminate or inactivate potentially autoreactive B cells are mechanisms of central 
tolerance33.  Central tolerance is critical in limiting autoimmunity caused by autoreactive 
lymphocytes33.  Immature B cells that survive central tolerance in the bone marrow 
migrate to the spleen via the blood to complete the developmental process33. 
Immature B cells that migrate to the spleen are called transitional B cells33.  The 
processes governing transitional B cell development are not well defined33.  What is 
known is that transitional B cells must interact with a self-antigen with moderate affinity, 
otherwise they die by apoptosis57. This process is called positive selection33.  
Conversely, if these cells bind to self-antigen too strongly, then they are eliminated from 
the repertoire by negative selection57.  The molecular mechanisms that underlie positive 
and negative selection are not well understood, but recent studies have begun to shed 
light on these processes.   
The pre-B cell checkpoint is regulated in part by the balance of the transcription 
factors BCL6 and BACH258.  Pre-BCR signaling positively regulates Bcl6 expression58.  
BCL6 in turn promotes the survival of pre-B cells by repressing the expression of DNA 
damage response and checkpoint genes (CHEK1, ARF, CDKN1A, and TP53) as well as 
the DNA damage sensor ATR58.  In contrast, BACH2 opposes BCL6 function and 
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executes negative selection of progenitor B cells with failed VH–DJH rearrangements58.  
BACH2 mediates these effects by downregulating antioxidant response genes and 
triggering a program of oxidative-stress-induced cell death58. BACH2 also increases the 
probability of a pre-B cell to undergo successful heavy chain rearrangement by 
increasing the expression and activity of the RAG recombinases58. 
Immature B cells in the bone marrow that express self-reactive BCRs activate 
classical NFκB via a NEMO/IKK-dependent pathway59.  One of the consequences is up 
regulation of BAFF-receptor on these cells, making them more responsive to BAFF-
dependent survival signals59.  Extended survival of these cells permits continual receptor 
editing that is required to generate κ+ immature B cells59.  
In the spleen, T1 transitional cells are extremely susceptible to apoptosis upon 
BCR stimulation, making them the target of negative selection against self-reactivity59.  
BCR-induced cell death is mediated by the mitochondrial pathway utilizing the pro-
apoptotic BH3-only domain proteins BAK, BAX, and BIM59.  NFκB is important at this 
stage as transfer of Rel-/- x Rela-/- fetal liver cells into irradiated hosts leads to a block at 
the T1 to T2 transition of development59.  The extreme sensitivity to apoptosis of the 
residual IgM+ cells in this genotype is partially rescued by a Bcl2 transgene; however, 
differentiation remains incomplete indicating that c-REL and RELA are required for 
differentiation as well as cell survival59.  However, BCR crosslinking in T1 transitional 
cells does not drive the activation of NFκB, suggesting that another receptor besides the 
BCR (such as the BAFFR) is driving NFκB activity in these cells59.  Conversely, BCR 
signaling in T2 transitional cells induces more long-term c-REL activation compared to 
T1 transitional cells, leading to increased expression of anti-apoptotic genes as well as 
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the prosurvival receptor BAFFR and its downstream substrate p100 (NFκB2)60.  
Moreover, lack of Nfkb1 and Nfkb2 leads to a block at the T2 stage59.  Together these 
studies suggest that NFκB is required for positive selection in T2 cells by promoting cell 
survival.  
A network of B cell transcription factors regulates B cell development 
Progression through B cell development is regulated by several transcription 
factors.  The B cell differentiation program is initiated at the earliest stages of B cell 
development through concerted regulation by the transcription factors PU.1, IKAROS 
(Ikzf1), and E2A (Tcf3).  All three of these transcription factors are expressed in HSCs30.  
Deletion of any one of these genes leads to a very early block in B cell 
development34,35,37–42,45,46,61 (Figure 1.1).  
The onset of B-lineage specification coincides with E2A-mediated activation of 
the transcription factor Foxo143,62 (Figure 1.2).  E2A and FOXO1 cooperatively 
upregulate the recombinase components Dntt (TdT), Rag1, and Rag2 in LMPPs30.  
Expression of these enzymes leads to DH to JH recombination in these early progenitors 
and may be the underlying mechanism that biases LMPPs to the B and T cell 
lineages30,63. PU.1, IKAROS, E2A, and FOXO1 collaborate to drive the expression of the 
interleukin-7 receptor (IL7R) α chain on CLPs30.  IL7R signaling leads to the activation of 
signal transducer and activator of transcription 5 (STAT5).  STAT5 cooperates with 
IKAROS, E2A and FOXO1 to upregulate the transcription factor early B cell factor 1 
(Ebf1)30,43,64–69.  EBF1, in turn, positively regulates E2a and Foxo1, forming a positive-
feedback loop that stabilizes Ebf1, E2a, and Foxo1 expression43,69,70. 
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EBF1 is critical in the specification of the B cell lineage.  Its expression is 
restricted to the B lineage within the hematopoietic system71,72.  Deficiency in Ebf1 leads 
to an early block in B cell development19 (Figure 1.1).  Moreover, the B cell progenitors 
that do arise in Ebf1-/- mice fail to upregulate many B cell specific genes19,67,70,73.  EBF1 
acts as a “pioneer” transcription factor that increases the accessibility of target genes to 
other transcription factors and histone modifiers43,74.  EBF1 cooperates with E2A and 
FOXO1 to activate many B-lineage–restricted genes, thereby promoting B-lineage 
specification69,73,75.   This is supported by the observation that ectopic expression of 
EBF1 in HSCs skews cells to enter the B lineage76.  Therefore, EBF is necessary in the 
early events of B cell development, including B lineage specification. 
EBF1 is also important in the commitment and maintenance of the B lineage.    
EBF1 promotes commitment by directly repressing genes that are critical for 
specification to alternative lineages, including Tcf7, Gata3, Cebpa, and Id277–79.  Ebf1-/- 
lymphoid progenitors retain T, NK, myeloid, and dendritic cell potential67,70,79, but ectopic 
expression of Ebf1 limits specification to these alternative lineages and promotes B cell 
differentiation76,79.  EBF1 is also required for the maintenance of B cell identity.  Deletion 
of Ebf1 in pro-B cells induces dedifferentiation into progenitors capable of giving rise to T 
cells and innate lymphoid cells77.  Therefore, EBF1 is necessary for the specification, 
commitment, and maintenance of the B lineage. 
EBF1 also promotes B cell development by guiding and redistributing other 
transcription factors such as E2A and PU.1 to genes involved in B cell specification69,80.  
This redistribution likely affects the differentiation program that E2A and PU.1 instruct.  
PU.1, for example, promotes both B cell and myeloid development80,81.  However, the 
distribution of PU.1 is dramatically different between these lineages80.  Moreover, the 
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PU.1 distribution in the B lineage is dependent on EBF180.  Therefore, EBF1 
redistributes the binding of PU.1 and E2A to genes that promote B cell development. 
EBF1 cooperates with PU.1, IKAROS, E2A, and FOXO1 to drive the expression 
of PAX5 30,32,75,82.  PAX5, in turn, feeds back to further drive the expression of Ebf1; thus 
creating a self-stabilized network of B cell specific transcription factors30 (Figure 1.2). 
PAX5 has a similar although not identical role as EBF1 in B cell development.  
Like EBF1, PAX5 is exclusively expressed within the B cell lineage of the hematopoietic 
system32.  Mice deficient for Pax5 have a block at the early pro-B to late pro-B transition 
of B lymphopoiesis, which is slightly later than that seen in Ebf1-/- mice83 (Figure 1.1).  
Moreover, Pax5-/- pro-B cells fail to recombine middle and distal VH segments to DJH 
segments83.  This is because PAX5 is required for µH chain contraction84, which 
juxtaposes distal VH segments with DH segments to increase distal VH to DJH 
recombination.  PAX5 also promotes µH chain recombination by cooperating with E2A, 
IKAROS, and EBF1 to increase the accessibility of the µH chain locus85.  However, 
ectopic expression of a rearranged µH chain in Pax5-/- lymphoid progenitors does not 
rescue B cell development86.  This is probably in part because PAX5 is required for the 
expression of many pre-BCR signaling components including Vpreb1, Igll1, Cd79a, Blk, 
and Blnk 87–90.  This is supported by the observation that ectopic expression of the pre-
BCR adaptor BLNK in Pax5-/- progenitors partially rescues pre-BCR signaling90.   
In addition to inducing genes involved in pre-BCR signaling, PAX5 also 
upregulates an additional 165 genes involved in transcriptional regulation, adhesion, 
migration, antigen presentation, and B cell differentiation91,92.  This transcriptional 
regulation by PAX5 promotes B cell specification91,92.  One third of PAX5 targets are 
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occupied by EBF1, suggesting that EBF1 and PAX5 cooperate to promote B cell 
specification75.  The cooperative regulation by EBF1 and PAX5 is most extensive for 
genes involved in pre-BCR signaling75, which are synergistically upregulated by EBF1 
and PAX578.   
PAX5 also cooperates with pre-BCR signaling to upregulate the transcription 
factors Irf4 and Irf887,92–95, which then drive Ikaros expression96.  IKAROS feeds back to 
positively regulate Ebf1, Pax5, and Foxo168.  IRF4, IRF8, IKAROS, FOXOs, and E2A 
then cooperate to promote Igκ recombination and pre-B cell differentiation50,68,97–102. 
In addition, PAX5 promotes B cell commitment and maintenance.  Unlike their 
WT counterparts, Pax5-/- pro-B cells can differentiate into macrophages, granulocytes, 
dendritic cells, natural killer cells, and T cells103–106.  This suggests that Pax5 is required 
for B lineage commitment.  However, forced Ebf1 expression can restore lineage 
restriction in Pax5-/- progenitors78,79.  This suggests that EBF1 can commit cells to the B 
lineage independently of PAX5 and that PAX5 potentially commits cells to the B lineage 
by upregulating Ebf1.  In addition, deletion of Pax5 in committed pro-B or mature B cells 
results in dedifferentiation and regained T lineage potential107,108.  Therefore, PAX5 is 
necessary for the maintenance of B cell identity and for B cell commitment, potentially by 
upregulating Ebf1.  
EBF1 and PAX5 continue to be expressed through the remainder of B cell 
development30.  It is not until B cells terminally differentiate into plasma cells that EBF1 
and PAX5 expression is lost30.  At that point, B cells turns off most B cell specific genes 
and terminally differentiate into plasma cells30.  The transcriptional network in plasma 
cells is instead dominated by the transcription factor BLIMP49,109.
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The Cd79a (Igα) locus has been studied extensively and provides a detailed 
example as to how a B cell specific gene is regulated in B cell development110.  Igα is a 
critical signaling component of the pre-BCR and the BCR.  The rate-limiting step in its 
transcriptional activation is the binding of EBF1 to the Cd79a locus30.  EBF1 then recruits 
E2A and RUNX130.  These transcription factors then collaborate to recruit histone 
demethylases, which in turn begin to demethylate and open the Cd79a promoter30.  As 
demethylation propagates, it unmasks a key PAX5/ETS composite binding site30.  This 
site then cooperatively binds PAX5 and the pan-lymphoid transcription factor, ETS130.  
PAX5 and ETS1 then recruit SWI/SNF chromatin remodeling complexes111, which then 
further increase accessibility and expression30. 
B cell development is controlled by a network of transcription factors.  B cell 
specification begins with the expression of PU.1, IKAROS, and E2A, which initiate a 
cascade of events that result in the expression of EBF1 and PAX5.  EBF1 and PAX5 
form a self-reinforcing network along with PU.1, IKAROS, E2A, and FOXO1 to specify 
and commit cells to the B lineage. Ultimately this network of transcription factors 
promotes and facilitates the differentiation of lymphoid progenitors into mature B cells.  
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Figure 1.2. The induction of a self-reinforcing B cell transcriptional network 
promotes B cell development.   
Hematopoietic stem cells (HSCs) and multipotent progenitor cells (MPPs) express a 
variety of transcription factors that can promote myeloid and/or lymphocyte 
development.  The induction of Foxo1 and Ebf1 form a self-reinforcing network that 
specifies cells to the B lineage and limits alternative lineage potential.  This network 
induces Pax5, which further reinforces the B cell differentiation program to promote VH to 
DJH recombination and pre-BCR expression.  Pre-BCR signaling positively regulates 
Foxo1, Ikaros, and E2a, which then induce light chain recombination.  The activation of 
NFκB by the B cell receptor (BCR) and B cell activating factor receptor (BAFFR) is 
necessary for the survival of immature B cells.  The expression of EBF and PAX5 in 
immature and mature B cells is critical to maintain B cell identity. 
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Signal transducer and activator of transcription 5 (STAT5) 
Structure and function of STAT5 
STAT5 exists in two isoforms, STAT5a and STAT5b, which exhibit 96% sequence 
identity.  They are ubiquitously expressed and functionally interchangeable112.  STAT5a 
and STAT5b contain an N-terminal domain that promotes dimerization, a DNA binding 
domain, an SH2 domain, and a C-terminal transactivation domain112 (Figure 1.3).  These 
proteins are encoded by STAT5a and STAT5b, which are separated by less than 14,000 
base-pairs (bp) in the genome48,112–114.  Mice lacking either Stat5a or Stat5b have mild 
defects in mammary development or growth hormone regulation and liver enzyme 
production, respectively115,116.  It remains unclear whether this is due to differences in 
function or expression of STAT5a versus STAT5b112.  STAT5a and STAT5b compensate 
for one another as mice lacking both Stat5a and Stat5b exhibit a perinatal lethal 
phenotype and have defects in erythropoiesis and B and T cell development47,48.  
Conditional deletion of Stat5a and Stat5b in B cells arrests B cell development at the 
CLP to pre-pro-B cell transition47 (Figure 1.1).  Therefore STAT5a and STAT5b have 
redundant roles in promoting early B cell development. 
	  	   17	  
a, Prior to activation, STAT5 exists as a homodimer organized in an anti-parallel head to 
head fashion that is mediated via interactions between the N-terminal domains.  b, 
Phosphorylation of the regulatory tyrosine (Tyr-694 and Tyr-699 in the case of STAT5a 
and STAT5b, respectively) results in binding of this phosphorylated tyrosine residue to 
the SH2domain of a neighboring STAT5a or STAT5b molecule and the generation of a 
novel parallel homodimeric configuration that can translocate to the nucleus, bind DNA, 
and modulate gene transcription (LHH 2011 review). 
 
STAT5 regulates early B cell development 
STAT5 activation is regulated by various cell surface receptors.  In progenitor B 
cells, IL7R signaling activates STAT5.  The IL7R is composed of two subunits, the IL7Rα 
and common γ (γc) chains, which associate with the tyrosine kinases JAK1 and JAK3, 
respectively.  Upon binding to its ligand, IL7, the IL7R brings JAK1 and JAK3 in close 
proximity to each other.  This proximity allows JAK1 and JAK3 to transphosphorylate 
one another, thus activating them.  The active JAKs then phosphorylate a tyrosine on 
the IL7Rα chain, which then recruits STAT5.  Prior to activation, STAT5 exists as a 
homodimer organized in an anti-parallel head to head fashion that is mediated via 
interactions between the N-terminal domains of STAT5112 (Figure 1.3). The JAKs 
phosphorylate recruited STAT5 (pSTAT5) at Tyr-694 (STAT5a) or Tyr-699 (STAT5b)112.  
a
b
Figure 1.3. Schematic of the STAT5 proteins.  	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This phosphorylation causes these tyrosine residues to bind to the SH2 domain of a 
neighboring STAT5a or STAT5b molecule and generates parallel homodimers that can 
translocate to the nucleus, bind DNA, and modulate gene transcription112,117–121. 
Once in the nucleus, STAT5 can function as an activator or repressor of 
transcription.  STAT5 can activate target gene transcription by recruiting the coactivator 
p300 or histone deacetylases (HDACs)122–124.  Conversely, STAT5 can also repress 
transcription by instead recruiting the corepressors SMRT or EZH2120,125.  The 
consensus DNA binding sequence for STAT5 is TTCxxxGAA, in which “x” is any base 
pair126.  However, STAT5 can also bind to imperfect consensus sites, particularly if a 
second STAT5 site is within 6-7 bp120.  Such neighboring STAT5 sites recruit STAT5 as 
a tetramer117,118.  There is evidence to suggest that tetrameric sites preferentially lead to 
target gene repression rather than activation120.  However, this is not true for all loci127.  
Therefore, STAT5 can recruit multiple co-activators and co-repressors to promote and 
inhibit target gene expression.  
The IL7R is first expressed at the CLP stage and peaks at the pro-B cell stage.  
Then IL7R levels begin to decrease in pre-B cells and are largely absent in immature 
and mature B cells.  Expression of constitutively active STAT5b mostly restores B-
lymphopoiesis in the absence of Il7r128, suggesting that IL7R promotes early B cell 
development primarily by activating STAT5.  One way that STAT5 promotes early B cell 
development is by positively regulating Ebf164–67.  In addition, STAT5 drives proliferation 
in progenitor B cells by upregulating Myc, Ccnd2, and Ccnd3101,128,129.  STAT5 also 
promotes the survival of progenitor B cells by positively regulating of Bcl2l1 (BCL-XL), 
Bcl2, Mcl1, and Pim13,128,130.  Therefore, STAT5 drives the development and expansion 
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of early B cell progenitors by positively regulating Ebf1 and genes involved in cell cycle 
progression and survival. 
STAT5 also regulates immunoglobulin recombination.  For example, STAT5 
promotes the recombination of distal VH segments in B cell progenitors3.  However, 
STAT5 also binds to the Igκ intronic enhancer (Eκi) and represses Igκ accessibility and 
recombination3,97,120.  This potentially limits progenitor B cells from recombining the light 
chain before heavy chain.  Thus, STAT5 promotes µH chain recombination but inhibits 
light chain recombination.  In summary, STAT5 promotes B cell development in early B 
cell progenitors, but potentially inhibits later stages of B cell differentiation by repressing 
light chain recombination. 
Pre-B cells escape IL7R signaling 
In order to promote efficient light chain recombination and differentiation, small 
pre-B cells escape IL7R signaling by several mechanisms.  As large pre-B cells exit the 
cell cycle and differentiate, they no longer respond to IL7131.  Yet these cells express a 
similar level of IL7R compared to proliferating large pre-B cells131.  One difference is that 
large pre-B cells that have exited the cell cycle express higher levels of the JAK-STAT 
inhibitor, Socs1, than proliferating large pre-B cells131.  Another molecule that could be 
responsible for IL7 insensitivity is the adaptor BLNK.  BLNK expression increases during 
pre-B cell differentiation102 and has been shown to bind to JAK3 and inhibit the activation 
of STAT5132.  Additionally, pre-B cells may escape IL7 signaling by moving away from 
IL7-producing stromal cells within the bone marrow133.  Pre-BCR signaling positively 
regulates the transcription factor IRF4, which upregulates the chemokine receptor 
Cxcr4133.  Cell may migrate in response to the corresponding chemokine CXCL12 to 
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areas of low IL7 concentration133.  Therefore, there are several potential mechanisms by 
which pre-B cells can lose IL7 sensitivity.  
Pre-BCR Signaling 
Structure and proximal signaling of the Pre-BCR 
Each pre-BCR is composed of two µ heavy chains, two surrogate light chains 
(each with one λ5 and one VPREB1), and a heterodimer of Igα and Igβ.  Disulfide bonds 
hold the two heavy chains together and each heavy chain with a surrogate light chain.  
Igα and Igβ each contain an extracellular Ig-like domain that associates with the µH 
chain through hydrophilic interactions.  Importantly, each Igα and Igβ also contains an 
immunoreceptor tyrosine-based activation motif (ITAM) located in the cytoplasm.  The 
ITAMs associate with the Src family kinase BLK, FYN, and LYN via low-affinity 
interactions in the absence of ITAM phosphorylation33. 
Pre-BCR signaling can be triggered by ligand dependent and independent 
mechanisms134.  Several self-antigens that induce pre-BCR signaling have been 
identified133.  However, it is unknown whether self-antigens are required for normal pre-
BCR signaling85,134.  Pre-BCR signaling can also be induced independently of antigens 
by inter-pre-BCR interactions involving the binding of λ5 (Igll1) on one pre-BCR to the 
µH chain on another pre-BCR85.  Therefore, the exact mechanisms that initiate pre-BCR 
signaling in vivo are not well understood and may or may not involve the binding of the 
pre-BCR to self-antigens. 
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Pre-BCR signaling induces BLK, FYN, and LYN to phosphorylate tyrosine 
residues within the ITAMs.  Phosphorylated ITAMs then recruit the tyrosine kinase SYK 
to the plasma membrane, thereby activating SYK.  Active SYK then phosphorylates the 
adaptor BLNK, rendering it active.  BLNK then facilitates many of the effector signaling 
pathways downstream of the pre-BCR such as FOXO proteins, ERK, and 
IKAROS/AIOLOS.33. 
Pre-B cell proliferation 
Upon rearrangement of the µH chain, large pre-B cells undergo 2-5 cell divisions, 
followed by cell cycle arrest, light chain recombination, and differentiation135.  This 
proliferative burst requires PI3K signaling136–138, which is probably driven by the IL7R 
and potentially the pre-BCR133,134.  The complete mechanism underlying pre-B cell 
proliferation is unclear133.  It is possible that the pre-BCR has two signaling states:  one 
that drives proliferation and another that promotes differentiation133.  Such a pro-
proliferative signaling pathway downstream of the pre-BCR has yet to be identified133.  
However, recent studies have begun to elucidate how progenitor B cells shift from a 
proliferative state to a quiescent state.  
Switch to pre-B cell differentiation 
The switch from a proliferative state to a quiescent state that promotes pre-B cell 
differentiation involves several signaling molecules.  IL7R signaling actives STAT5 and 
PI3K, which positively regulate the transcription factor Myc85,129.  MYC, in turn, promotes 
proliferation by upregulating Ccnd385.  However, MYC also initiates a negative feedback 
loop by activating p19Arf85.  p19Arf suppresses the E3 ubiquitin ligase MDM2, which 
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itself inhibits p53 stability.  Thus, MYC activation of p19Arf stabilizes p53 and promotes 
cell cycle arrest85.  This pathway may be an important mechanism by which pre-B cells 
promote quiescence.   
In addition, PI3K-AKT signaling activates mTORC1, which then upregulates 
Pax585.  Similarly, active STAT5 positively regulates Ebf1.  PAX5 and EBF1 then 
upregulate many of the genes involved in pre-BCR signaling, including Vpreb1, Igll1, 
Cd79a, Cd79b, Blk, and Blnk75,87.  Once expressed, the pre-BCR promotes cell cycle 
arrest and light chain rearrangement by activating FOXOs, ERK, and IKAROS/AIOLOS. 
Pre-BCR signaling activates FOXO proteins 
Initially, BLNK is expressed at low levels in pre-B cells134.  However, BLNK levels 
increase due to positive regulation by EBF1 and PAX587,139.  Once BLNK activity passes 
a certain threshold, it negatively regulates PI3K signaling99 (Figure 1.4).  This then 
alleviates the negative regulation of FOXO proteins by PI3K85.  BLNK can also positively 
regulate FOXOs by activating p3898,99,102,140.  Moreover, IL7 activation of STAT5 drives 
Ebf1 expression, which also positively regulates Foxo170.  This forms a positive 
feedback loop whereby FOXO proteins bind and upregulate Syk and Blnk102, which in 
turn positively regulate FOXOs.  FOXOs also promote cell cycle arrest by positively 
regulating the cell cycle inhibitors Cdkn1b (INK4B / p27Kip1) and Cdkn2a (ARF and 
INK4A)85.  In addition, FOXO proteins bind to and upregulate Rag1 and Rag2 and 
promote Igκ recombination98,99.  To summarize, FOXO proteins are important in forming 
a positive feedback loop with BLNK that promotes cell quiescence and Igκ 
rearrangement. 
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Signaling via the IL7R activates the transcription factor STAT5 and the kinases PI3K and 
AKT, which promote pre-B cell proliferation and inhibit light chain recombination.  PI3K-
AKT does this in part by suppressing FOXO proteins.  Expression of the pre-BCR leads 
to the activation of the kinase SYK and the adaptor BLNK.  SYK and BLNK in turn 
positively regulate FOXOs, IKAROS, AIOLOS, and E2A, which promote cell cycle arrest 
and light chain recombination.  BLNK also negatively regulates JAK3-STAT5 and PI3K 
signaling.  This alleviates FOXOs of negative regulation by PI3K-AKT.  FOXOs, 
IKAROS, and E2A form a positive feedback loop by further inducing SYK and BLNK 
activity.  Paradoxically, IKAROS and AIOLOS also form a negative feedback loop by 
suppressing the expression of the surrogate light chain components Vpreb1 and Igll1 
(λ5). 
 
Pre-BCR signaling activates the RAS-ERK pathway 
BLNK also activates the RAS-ERK pathway by recruiting the adaptor GRB2 and 
the enzyme PLCγ1/2141,142.  The RAS-ERK pathway is necessary for pre-B cells to exit 
the cell cycle and recombine the Igκ locus101,143.  ERK seems to promote cell cycle arrest 
by inhibiting Ccnd3 expression in pre-B cells101.  However, ERK induces 
Igκ recombination by a separate mechanism.  ERK promotes E2A activity by inducing 
E2a expression and by repressing the E2A inhibitor Id3101.  E2A then upregulates 
pre-BCR
SYK
BLNK
IRF4/8
IKAROS
AIOLOS
RAS
ERK
E2A
Proliferation
Igκ/λ recombination
JAK3
STAT5
IL7R
PI3K
AKT
FOXO
Figure 1.4. IL7R and pre-BCR signaling pathways have opposing roles in pre-B 
cells.	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Foxo1102.  E2A cooperates with FOXO1 to promote Igκ recombination by upregulating 
the recombinase components Rag1, Rag2, and Dntt (TdT) and by opening the Igκ 
locus85,98,99,101,144.  E2A also increases accessibility to the Igκ locus by binding to the Igκ 
intronic enhancer (Eκi) and the Igκ 3’ enhancer (Eκ3)101,145,146.  Pre-BCR activation of 
RAS-ERK is necessary for pre-B quiescence and light chain recombination. 
Pre-BCR signaling positively regulates the IRF4/8-IKAROS/AIOLOS pathway	  	  
The pre-BCR also promotes pre-B cell differentiation by upregulating Irf4, Irf8, 
Ikaros, and the Ikaros family member Aiolos (Ikzf3).  More specifically, BLNK activity 
induces Irf4 and Irf894,147,148, which upregulate Ikaros and Aiolos94,96,149.  AIOLOS has 
70% overall homology with IKAROS and this homology is particularly extensive in the 
DNA binding and C-terminal domains150.  Unsurprisingly, the binding of IKAROS and 
AIOLOS overlaps considerably at loci throughout the genome151.  Moreover, IKAROS 
cooperates with AIOLOS to inhibit the expression of Ccnd2, Ccnd3, and Myc and 
promote cell cycle arrest in pre-B cells94,96,135,152,153.  In addition, IRF4, IRF8, and 
IKAROS promote Igκ recombination50,68,97.  Finally, IKAROS and AIOLOS cooperate in a 
negative feedback loop by inhibiting the expression of the pre-BCR components Igll1 
(λ5) and Vpreb150,94,96,154.  Pre-BCR induction of Irf4, Irf8, Ikaros, and Aiolos is necessary 
for pre-B cells to exit the cell cycle, induce light chain recombination, and differentiate 
into immature B cells. 
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Deregulation of B cell development promotes ALL 
A network of B cell transcription factors, STAT5 and pre-BCR signaling 
coordinately promote the generation of B cells in the bone marrow.  However, mutations 
in these same processes can lead to the transformation of B cell progenitors and cause 
B-ALL.  There are several ways that B cell progenitors can become transformed.   
Deregulation of B cell transcriptional network in B-ALL 
Recurring chromosomal translocations and mutations are a hallmark of B-ALL 
and contribute significantly to the diagnosis and prognosis of this disease9,112,155.  The 
most commonly altered pathway in B-ALL is the transcriptional regulation of B cell 
development9.  B-ALL is also characterized by a block in B cell differentiation9.  
Unsurprisingly, the genes that regulate the early stages of B cell development, IKAROS, 
PAX5, and EBF1, are frequently mutated in B-ALL9.  These mutations result in loss of 
function deletions, dominant negative deletions, or gene fusions that lead to an arrest in 
B cell development134.  
The role of PAX5 in B-ALL 
The most common loss of function mutations in B-ALL are found in the PAX5 
locus (32% of patients)9,26.  These mutations consist of predominantly mono-allelic 
deletions that sometimes involve a larger segment of chromosome 9p and point 
mutations15,17.  Less frequently, PAX5 mutations are found in the form of chromosomal 
translocations, which drive the expression of various fusion proteins15.  The most 
common PAX5 fusion proteins in B-ALL include PAX5-ETV6, PAX5-C20orf112, PAX5-
FOXP1 and PAX5-PML17,108.  PAX5 mutations are detected in virtually all B-ALL 
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subtypes, but occur more frequently in BCR-ABL+ cases (54%)26.  BCR-ABL is a fusion 
protein consisting of break point cluster region (BCR) and the kinase ABL1 that results 
from a translocation of chromosomes 9 and 22.  The BCR-ABL1 translocation drives the 
expression of a highly active kinase that phosphorylates many downstream targets to 
drive leukemia.  PAX5 mutations are not associated with adverse outcomes, however, 
they are important in leukemogenesis9. 
The mechanism by which PAX5 mutations promote B-ALL varies and depends 
on the type of mutation.  The PAX5 fusion proteins function as dominant-negatives by 
multimerizing and binding with high avidly to target genes156.  This prevents the WT 
PAX5 from binding and modulating gene expression156,157.  The more common deletions 
and point mutations typically occur in only one PAX5 allele, suggesting that these 
genetic alterations result in haploinsufficiency or hypomorphic alleles108,158.  However, B 
cell development is normal in Pax5+/– mice2,159,160.  This may be because monoallelic 
mutations in PAX5 require secondary mutations to drive ALL.  This is supported in mice, 
as Pax5 heterozygosity cooperates with STAT5 activating mutations to initiate B-
ALL2,161,162.  Similarly, PAX5 deletions are frequently found in human B-ALL samples that 
also harbor BCR-ABL or TCF3-PBX1 translocations or CDKN2A deletions17,26,158,163, 
suggesting that PAX5 deletions cooperate with these mutations to drive B-ALL.  Pax5 is 
also known to induce the expression of the tumor suppressor Bach2164.  Ectopic 
expression of Bach2 suppresses B-ALL induced by MYC or BCR-ABL by activating p53 
and thereby causing apoptosis134,164.  Therefore, PAX5 may suppress ALL, in part, by 
upregulating Bach2.  This also might explain why PAX5 mutations are common in BCR-
ABL+ leukemias - potenitally as a means to inactivate BACH2.  In summary, PAX5 
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mutations can function as dominant negatives or cooperate with other secondary 
mutations to promote B-ALL.  
The role of IKAROS in B-ALL 
The second most common genetic deletions in B-ALL occur in the IKAROS 
locus. Deletions of IKAROS are found in 28% of patients with B-ALL26.  Moreover, 
IKAROS deletions have clinical significance, as they are associated with poor clinical 
outcome165–167.  IKAROS deletions result in loss of function or dominant negative 
isoforms of IKAROS9.  The dominant negative form of IKAROS results from a deletion of 
exons 4-7168, which is likely mediated by off target effects of RAG1/2169.  This causes in-
frame splicing of exon 3 to exon 8 and expression of an isoform called Ik6168.  This Ik6 
isoform localizes to the cytoplasm due	  to the loss of the DNA binding domain and the 
nuclear localization sequence170–172.  The Ik6 isoform acts as a dominant negative by 
sequestering normal IKAROS proteins in the cytoplasm, as well as other IKAROS family 
members including AIOLOS150,169,173.  Approximately 33% of all IKAROS deletions found 
in B-ALL result in the expression of Ik6169.  
IKAROS deletions can also result in no IKAROS expression.  This is caused by 
biallelic deletions that result in 2 null alleles169.  Biallelic deletions comprise 12% of all 
IKAROS deletions in B-ALL169.  The majority of IKAROS deletions (55%), however, 
result in haploinsufficiency169.  In mouse models, deficiency in one IKAROS allele 
accelerates BCR-ABL-driven leukemia174.  These leukemic cells show a 50% reduction 
in the expression of full-length IKAROS, as expected174.  These studies illustrate that 
monoallelic deletions in IKAROS can result in haploinsufficiency and accelerate 
leukemia174.  
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The various types of IKAROS deletions are disproportionally found in different 
subtypes of ALL.  For instance, up to 70% of IKAROS mutations found in BCR-ABL+ B-
ALL exhibit severe IKAROS deletions (null or dominant negative)170,175,176.  
Haploinsufficiency, however, is more common in BCR-ABL negative B-ALL (57-72% of 
IKAROS mutations)166,170.  These observations suggest that the selective pressure to 
acquire severe IKAROS mutations is higher in BCR-ABL+ B-ALL than other subtypes169.  
IKAROS deletions are highly enriched for B-ALL cases that are BCR-ABL+ or BCR-ABL-
like, as 84% of BCR-ABL+ and 39% of BCR-ABL-like B-ALL cases have IKAROS 
deletions165,175.  BCR-ABL-like cases express a similar gene signature as BCR-ABL+ B-
ALL samples, but are BCR-ABL negative177.  Some of the genes that are commonly 
deregulated in BCR-ABL-like cases include deletions of B cell transcription factors and 
mutations that activate STAT5 such as IGH-CRLF2 and TEL-JAK2 translocations9,177,178.  
Patients with BCR-ABL+ or BCR-ABL-like B-ALL tend to respond more poorly to therapy 
and have poorer outcomes than patients with other forms of B-ALL9.  These 
observations suggest that IKAROS deletions cooperate with genes that control a BCR-
ABL gene signature that is associated with high-risk cases of B-ALL.   
In mice, null mutations and dominant negative forms of Ikaros tend to drive T-
ALL rather than B-ALL36,179,180.  In humans, however, IKAROS deletions are rarely 
observed in T-ALL (5% of cases)181–183.  Therefore, IKAROS may play a more important 
role in suppressing T-ALL in mice compared to in humans.  
How IKAROS deletions promote B-ALL is not completely clear.  Gene expression 
signatures associated with loss of IKAROS in B-ALL have revealed an overexpression of 
genes indicative of a stem cell phenotype166,184.  Moreover, IKAROS is known to silence 
stem cell genes in lymphoid progenitors40.  Thus, IKAROS deficiency might promote self-
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renewal by inducing a stem cell gene expression pattern169.  IKAROS mutations may 
also promote B-ALL by blocking B cell development, as mice with loss-of-function 
mutations in Ikaros exhibit blocks at various stages of B cell development34,35,37–40,61 
(Figure 1.1).  IKAROS is required for HSC activity38, the rearrangement of the heavy and 
light chains68,169,185, and the expression of genes involved in B cell specification and 
commitment61,186.  In addition, loss of IKAROS may promote transformation by 
preventing cell cycle arrest169.  This is supported in mice as IKAROS induces and is 
required for pre-BCR-mediated exit from the cell cycle in BCR-ABL+ pre-B 
cells35,36,94,153,174.  IKAROS promotes cell cycle arrest in pre-B cells by binding to and 
inhibiting Myc and Ccnd2 expression152,187.  IKAROS also promotes exit from the cell 
cycle by redirecting SYK phosphorylation of BLNK to tyrosine 96 (Y96)153,188.  
Phosphorylation of BLNK at Y96 preferentially activates a BLNK-dependent tumor 
suppressor pathway that induces Cdkn1b (p27Kip1) and cell cycle arrest132.  Finally, 
conditional deletion of Ikaros starting in CLPs has been shown to promote B-ALL by 
enhancing integrin-mediated survival, proliferation, and self-renewal35.  Therefore, 
IKAROS suppresses ALL potentially by increasing self-renewal capabilities, causing a 
block in B cell development, inhibiting proliferation, and/or inhibiting cell survival.   
The role of EBF1 in ALL 
Deletions of EBF1 are found in 4-7% of B-ALL cases and can occur on one or 
both alleles158,189,190.  These deletions are variable in size, but frequently affect a large 
portion of the EBF1 open-reading frame, suggesting a loss-of-function phenotype17.  
Complete loss of Ebf1 in mice causes an arrest in B-cell development at the pro-B-cell 
stage19, suggesting that bi-allelic deletions of EBF1 may promote B-ALL by blocking B 
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cell differentiation.  Ebf1+/- mice, on the other hand, display a 50% reduction in pro-B 
cells19, but do not develop leukemia2.  However, Ebf1 heterozygosity cooperates with 
constitutive active STAT5b to drive B-ALL2.  Similarly, EBF1 deletions are more 
prevalent in BCR-ABL+ cases (14%) and BCR-ABL-like B-ALL cases (38%)190.  
Additionally, Monoallelic deletions of EBF1 occur more frequently in combination with 
BTG1 gene deletions (26%)191, suggesting that these tumor-suppressors may cooperate 
to promote B-ALL17.  Deletions of EBF1 may contribute to B-ALL by blocking B cell 
development or by cooperating with secondary mutations. 
The role of STAT5 in ALL 
The two most common oncogenic translocations in B-ALL are ETV6-RUNX1 
(TEL-AML1) and BCR-ABL14.  Both of these translocations activate STAT51,192,193.  
ETV6-RUNX1 is found in up to 25% of pediatric B-ALL cases and 2% of adult B-ALL 
cases6,14.  Where as BCR-ABL is found in 25% of adult B-ALL cases and 2% of pediatric 
B-ALL patients14.  Moreover, high levels of active STAT5 are associated with poor 
prognosis in BCL-ABL+ leukemias2.  In addition, several other mutations found in B-ALL 
activate STAT5, including rearrangements of the kinases ABL1, ABL2 (ARG), CSF1R, 
EPOR, JAK2, PDGFRB and mutations in the cytokine receptors IL7R, CRLF2, and 
FLT39.  As previously mentioned, many of these STAT5-activating mutations are 
common in BCR-ABL-like B-ALL177.  In addition, activating mutations in STAT5 itself 
have also been identified in leukemia194–196.  Therefore, STAT5 is commonly 
hyperactivated in B-ALL and activation of STAT5 is correlated with patients that have 
high-risk forms of B-ALL and shorter overall survival.  
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Several of these mutations that activate STAT5 have been shown to require JAK-
STAT signaling to promote cell proliferation, including ETV6-RUNX1, CRLF2, IL7R, 
EPOR, EBF1-PDGRRB, and FLT3-ITD9,192,197–202.  Moreover, BCR-ABL, TEL-JAK2, and 
TEL-PDGFRB have been shown to require Stat5 to cause transformation in mice203–205.  
One of these studies showed that inducible deletion of Stat5a and Stat5b in BCR-ABL+ 
B-ALL cell lines induced cell cycle arrest and apoptosis203.  Therefore, STAT5 may 
initiate BCR-ABL-driven B-ALL by promoting proliferation and survival.  However, the 
molecular mechanisms underlying the role of STAT5 in B-ALL remain unclear.   
Pre-BCR and ALL 
Strong evidence suggests that pre-BCR signaling functions to suppress ALL.  
Moreover, many of the genes that encode pre-BCR signaling components are frequently 
disrupted in ALL.  
Deletions of one such pre-BCR signaling component, the adaptor BLNK, have 
been found ALL.  However, the exact frequency of BLNK mutations is not clear153,158,206–
208.  In one small study, 16 of 34 B-ALL samples had complete loss or dramatic 
reductions in BLNK expression207.  The decreased BLNK expression is probably due to 
deletions that cause alternative splicing of BLNK and expression of a dominant negative 
isoform207,208.  Moreover, BCR-ABL has been shown to induce similar alternative splicing 
of BLNK209.  In mice, Blnk has been shown to function as a tumor suppressor in pre-B 
cells132,210.  One way that BLNK has been proposed to suppress leukemia is by binding 
to JAK3 and inhibiting JAK-STAT5 signaling132.  BLNK inhibition of STAT5 leads to p27 
expression and cell cycle arrest132.  BLNK might also suppress B-ALL by activating the 
kinase BTK.  This is supported by the observation that constitutively active BTK prevents 
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leukemia caused by Blnk deficiency211.  BLNK may also suppress B-ALL by activating 
the tumor suppressor pathway IRF4/8-IKAROS/AIOLOS50,94,96,149,174,212,213, which 
promote cell cycle arrest and differentiation68,152.  In addition, BLNK positively regulates 
other potential tumor suppressor pathways such as FOXO and RAS-ERK85,99,101,214, 
which also promote cell cycle arrest and differentiation210.  Therefore BLNK suppresses 
B-ALL potentially by inhibiting JAK-STAT5 signaling and activating downstream 
pathways that promote cell cycle arrest and differentiation.   
FOXO proteins also appear to have a role in suppressing ALL.  FOXO3, for 
example, is decreased in B-ALL and T-ALL compared to healthy controls189,215.  
Furthermore, FOXO proteins function as tumor suppressors in mice216.  However, all 
three FOXO homologues, Foxo1, Foxo3, and Foxo4, must be deleted to cause 
transformation.  The resulting ALL originates from the T-lineage.  Therefore, FOXO 
proteins likely have a role in suppressing B-ALL but it has not been demonstrated that 
FOXOs function as tumor suppressors in B cell progenitors.  However, FOXOs are 
known to promote quiescence and Igκ recombination in progenitor B cells98,99,102,217, 
potentially by positively regulating the expression of a full-length isoform of IKAROS149.  
Therefore, FOXOs may suppress B-ALL by promoting cell cycle arrest and Igκ 
recombination.   
Another pre-BCR component that is disrupted in B-ALL is the kinase BTK218.  
However, the role of BTK in B-ALL is not clear.  In mice, BTK can suppress 
transformation independent of it kinase activity211,219, suggesting that it can suppress 
leukemia by functioning as an adaptor. 
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BTK positively regulates PLCγ2, which has also been shown to suppress B-ALL.  
Plcg2 deficiency in mice causes enhanced IL7 signaling and proliferation220.  In addition, 
Plcg2-/- pre-B cells have elevated levels of RAG1 and RAG2220, which may increase the 
chances of secondary mutations175,191,221,222.  Moreover, Plcg2 deficiency cooperates with 
the pro-proliferative factor MYC to initiate leukemia220.  Therefore, Plcg2 can suppress B-
ALL potentially by inhibiting proliferation. 
PLCγ2 positively regulates NFκB, which promotes cell proliferation and survival 
in immature and mature B cells60,90,142,147,223.  NFκB is also known to promote the survival 
of many other cell types224.  Consequently, NFκB drives transformation in many cell 
types, including B cell lymphomas224.  However, NFκB can also suppress tumorigenesis 
in some contexts and cell types including pre-B cells224.  Therefore, the role of NFκB in 
cancer is context-dependent.  There are several factors that can influence the activity of 
NFκB.  Post-translational modifications of NFκB, for example, regulate NFκB subunit 
dimerization, proteolytic degradation, and localization224.  Post-translational modifications 
can also determine whether NFκB induces or represses the expression of target 
genes224.  Others factors that modulate the function of NFκB include tumor suppressors, 
kinases, transcriptional regulators, or transcription factors224,225.  Tumor suppressors 
such as p53 and ARF can inhibit the tumor-promoting activities of NFκB subunits while 
simultaneously facilitate their ability to suppress cancer progression224.  Therefore, the 
role of NFκB in cancer is influenced by many factors and varies between cell types.   
In pre-B cells, NFκB1 has been shown to suppress v-ABL1-induced 
transformation, potentially by inhibiting Ccnd1 expression226.  Additionally, NFκB binds to 
the Igκ enhancer and promotes light chain rearrangement and differentiation227,228.  
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Thus, NFκB can suppress the transformation of pre-B cells, possibly by inhibiting 
proliferation and promoting light chain rearrangement. 
NFκB induces IRF4 and IRF8148,229–231, which have been shown to suppress B-
ALL in mice.  IRF4 deficiency cooperates with MYC to drive B-ALL213.  IRF4 also 
suppresses BCR-ABL-induced leukemia in mice, primarily by negatively regulating cell 
cycle progression50,232.  IRF4 and IRF8 seem to exhibit redundant roles in pre-B cells, as 
a deficiency in both factors invariably leads to B-ALL-like disease212.  Deficiency in just 
one of the other factors can lead to B-ALL but the penetrance is lower.  The mechanism 
is not clear but deficiencies in IRF4 and IRF8 may promote B-ALL by blocking B cell 
development, as is seen in mice44,50.  IRF4 and IRF8 may also suppress B-ALL by 
inducing IKAROS and AIOLOS96, which induce cell cycle arrest and Igκ 
recombination68,152.  Therefore, IRF4 and IRF8 can potentially suppress B-ALL by 
inhibiting proliferation and by promoting light chain recombination and B cell 
differentiation. 
Deletions in other pre-BCR signaling components such as SYK and VPREB1 
have also been reported in B-ALL165,218.  The mechanism by which these deletions drive 
disease may involve BCR-ABL, as BCR-ABL+ B-ALL samples consistently have a 
decrease in the expression of many pre-BCR signaling components:  VPREB1, IGLL1, 
IGHM, CD79A, CD79B, LYN, BLK, FYN, SYK, BLNK, PLCG2, IKK, IRF4, and 
IKAROS153,158,175,207,209,233.  Moreover, BCR-ABL activates many of the signaling 
components downstream of the pre-BCR, including SYK, BTK, and PLCγ1/2233.  This 
may cause pre-B cell activation above a signal strength threshold that causes negative 
selection or apoptosis233.  Therefore, BCR-ABL+ clones that express a functional pre-
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BCR are selected against153.  Pharmacological agonism of SYK induces cell death in 
BCR-ABL+ cells, but not when BCR-ABL is concomitantly inhibited with Imatinib233. 
These data suggest that pre-BCR signaling is important in the suppression of BCR-ABL+ 
B-ALL and that agonism of the pre-BCR signaling pathway might be effective in treating 
B-ALL.  To summarize, the deregulation of B cell transcription factors, STAT5 and pre-
BCR signaling can lead to the transformation of B cell progenitors.  
Super-enhancers 
General features of enhancers and super-enhancers 
Transcription factors typically regulate gene expression by binding cis-acting 
regulatory elements known as enhancers and by recruiting coactivators and RNA 
polymerase II (RNA Pol II) to target genes234.  Enhancers are segments of DNA that are 
generally a few hundred base pairs in length and are typically occupied by multiple 
transcription factors234.  The number of enhancers that are active in any one cell type 
has been estimated to be in the tens of thousands, and enhancer activity is largely cell-
type specific234.   
Recent studies have identified a new class of enhancers, termed super-
enhancers, which tend to regulate the most highly expressed genes in each cell type in a 
cell-type-specific manner234.  These super-enhancers appear to play a key role in cell 
identity and in diseases such as cancer and autoimmunity234–237.	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Role of super-enhancers in embryonic stem cells 
Super-enhancers have been most well characterized in embryonic stem cells 
(ESCs).  In ESCs, only a small number of master transcription factors control the gene 
expression program that establishes and maintains ESC state234,238–240.  These 
transcription factors, which include OCT4, SOX2, and NANOG, bind to enhancers 
together with the Mediator coactivator complex234,241.  The Mediator complex facilitates 
the ability of enhancer-bound transcription factors to recruit RNA Pol II to the promoters 
of target genes and is essential for maintenance of ESC state and embryonic 
development234,241–247. 
Whyte and colleagues found that ESC enhancers can be divided into two classes 
based on Mediator levels—one class comprised the vast majority (8,563) of enhancers, 
and the other encompassed 231 large enhancer domains, termed super-enhancers234.  
Approximately 40% of Mediator signal associated with the 231 super-enhancers by 
ChIP-Seq234. The key features of the super-enhancers are that (1) they span DNA 
regions whose median length is an order of magnitude larger than the typical enhancer 
and that (2) they have levels of Mediator that are at least an order of magnitude greater 
than those at the typical enhancer234. 
Super-enhancers can also be distinguished from typical enhancers in ESCs by 
the presence of the transcription factors KLF4 and ESRRB, which play important roles in 
the ESC gene expression program and in reprogramming of somatic cells to induced 
pluripotent stem cells234.  Super-enhancers were also enriched for sequence motifs 
bound by transcription factors important in ESC function, including OCT4, SOX2, 
NANOG, KLF4, and ESRRB234.  This indicates that super-enhancers are formed as a 
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consequence of binding of specific master transcription factors to dense clusters of their 
binding site sequences234.  
The set of super-enhancer-associated genes contained nearly all genes that 
have been implicated in control of ESC identity, including genes encoding the master 
ESC transcription factors OCT4, SOX2, and NANOG and DNA-modifying enzymes and 
MicroRNAs that control the ESC gene expression program234.  OCT4, SOX2, and 
NANOG form an interconnected autoregulatory loop in which all three factors bind as a 
group to the promoters of each of their own genes and form the core regulatory circuitry 
of ESCs234,248,249.  Therefore, the genes encoding the master transcription factors OCT4, 
SOX2, and NANOG are themselves driven by super-enhancers, forming feedback loops 
in which the key transcription factors regulate their own expression234. 
Super-enhancer-associated genes are generally expressed at higher levels than 
genes associated with typical enhancers234.  Luciferase assays have confirmed that 
super-enhancers tend to drive higher levels of transcription than typical enhancers234.  
The presence of KLF4 and ESRRB also correlates with high levels of luciferase activity, 
suggesting that high levels of the transcription factors KLF4 and ESRRB at super-
enhancers drive high-level expression of their target genes in ESCs234.   
Enhancers typically function through cooperative and synergistic interactions 
between multiple transcription factors and coactivators234,250–254.  The transcriptional 
output of enhancers with large numbers of transcription factor binding sites can be more 
sensitive to changes in transcription factor concentration than those with smaller 
numbers of binding sites234,255,256.  Similarly, super-enhancer-associated genes are more 
sensitive to loss of transcriptional networks than other genes, as reducing the levels of 
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OCT4 or Mediator lead to more profound effects on expression of super-enhancer-
associated genes than on other active genes with typical enhancers234. 
Super-enhancers in progenitor B cells 
Similar to those studies in ESCs, high levels of Mediator binding has been used 
to define super-enhancers in pro-B cells234.  The occupancy of Mediator highly correlates 
with the B cell transcription factor PU.1, which is predictive of enhancer activity234,257,258.  
Therefore this suggests that Mediator can also be used to predict enhancer activity in 
pro-B cells234.  Those 395 Mediator-defined super-enhancers in pro-B cells shared 
similar characteristics to those found in ESCs—they spanned DNA domains whose 
median length is an order of magnitude larger than the typical enhancer, and they had 
levels of Mediator that are at least an order of magnitude greater than those at typical 
enhancers234.  These pro-B cell super-enhancers were enriched for closely spaced 
clusters of the sequence motifs of several B cell transcription factors, including EBF, 
E2A and FOXO1234.  Those genes associated with pro-B cell super-enhancers featured 
those that are regulators of B cell identity including the B cell transcription factors Ikaros, 
Ebf1, and Foxo1, the IL7R kinase Jak1, and the pre-BCR signaling components Vpreb1, 
Igll1 (λ5), Cd79a (Igα), Cd79b (Igβ), Syk, Blnk, and Inpp5d234.  Therefore pro-B cell 
super-enhancers seem to be formed by a clustering of B cell transcription factors and 
associated with genes that are key to B cell development. 
Role of super-enhancers in transformation 
In transformed B cells (diffuse large B cell lymphoma or DLBCL), super-
enhancers have been shown to be enriched for BRD4, which is a member of the 
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bromodomain and extraterminal (BET) subfamily of human bromodomain proteins235,236.  
BRD4 binds to acetylated chromatin and recruits Mediator and the positive transcription 
elongation factor P-TEFb to such sites235,259–262.  This in turn leads to the recruitment of 
RNA Pol II and transcriptional activation235,259,263–265.   
Chromatin regulators such as BRD4 are attractive as therapeutic targets for 
cancer because they are deregulated in numerous cancers235,266–270 and are amenable to 
small-molecule inhibition235,261,271,272.  Most chromatin regulators, however, are 
expressed in a broad range of healthy cells and contribute generally to gene expression, 
so inhibition of these important genome-associated proteins might be expected to 
adversely affect global gene expression in healthy cells and thus produce highly toxic 
effects235.  Nonetheless, inhibitors of some chromatin regulators, such as BRD4, have 
been shown to selectively inhibit transcription of key oncogenic drivers such as MYC in 
multiple tumor types including multiple myeloma, Burkitt’s lymphoma, acute myeloid 
leukemia, and ALL235,236,261,273–276. 
The inhibition of MYC apparently occurs as a consequence of BRD4 depletion at 
the super-enhancers that drive MYC expression235,236,273,277. Treatment of multiple 
myeloma tumor cells with the BRD4 inhibitor JQ1, for example, causes a preferential 
loss of BRD4, Mediator, and P-TEFb at super-enhancers and preferential loss of 
transcription at super-enhancer-associated genes235.  These included genes that are 
important in cancer pathogenesis such as Myc, Ccnd2, Pim1, Mcl1, and Bcl2l1235,278–285.  
Similarly, JQ1 causes the preferential loss of expression of super-enhancer associated 
genes in DLBCL cell lines, including the DLBCL oncogenes Myc and Cd79b236,286.	  	   
 
	  	   40	  
BRD4 inhibitors have been shown to induce cell cycle arrest and/or apoptosis in 
several tumor cell types, including neuroblastomas, glioblastomas, medulloblastomas, 
breast cancer cells, erythroleukemias, acute myeloid leukemias, T cell acute 
lymphoblastic leukemias, and B-cell non-Hodgkin lymphomas277,287–295 .  BRD4 inhibitors 
have also been shown to inhibit tumor progression in mouse models of DLBCL, multiple 
myeloma, and mantle cell lymphoma235,277,296,297.  Importantly, BRD4 inhibition has been 
shown to induce cell cycle arrest and inhibit proliferation in human B-ALL samples and 
decrease leukemic burden and improve survival in B-ALL primary human xenograft 
models275.  Although BRD4 is widely expressed in mouse tissues, mice are reasonably 
tolerant of the levels of BET bromodomain inhibition that are used mouse models to 
suppress tumor growth235,261,273,274,276,298.  Therefore, BRD4 inhibitors may be safe and 
effective in treating a wide variety oncogene-addicted malignancies, including B-ALL275.  
Conclusions 
ALL is a common form of cancer in children, but is also found in adults.  It is 
caused by the transformation of lymphocyte progenitors, typically derived from the B-
lineage.  Normally, the development of B cells in the bone marrow generates a vast 
repertoire of mature B cells, capable of specifically recognizing and combating many 
different foreign pathogens.  B-ALL is frequently caused by genetic mutations in genes 
that control B cell development.  Common pathways that are deregulated in B-ALL 
include the B cell network of transcription factors, STAT5, and pre-BCR signaling.  
Mutations in some of the genes that make up these pathways are associated with high-
risk subgroups of B-ALL that currently have the worst prognosis.  How these pathways 
contribute to disease and how they interact to cause B-ALL is not well understood.  For 
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example, why are IKAROS deletions highly enriched in BCR-ABL+ and BCR-ABL-like 
leukemias?   
Super-enhancers are an emerging class of enhancers that have an important 
role in controlling cell identity, function, and transformation.  While super-enhancers 
have been identified in progenitor B cells, more extensive studies about how these 
super-enhancers interact with STAT5 or other B cell transcription factors have yet to be 
reported.  A better understanding of these transcriptional networks may elucidate the 
mechanisms by which oncogenes and tumor suppressors are regulated in progenitor B 
cells. 
My thesis is focused on understanding some of the underlying mechanisms by 
which the deregulation of B cell transcription factors, STAT5, and pre-BCR signaling 
cause ALL.  Moreover, I aim to elucidate how these pathways interact and cooperate to 
initiate disease.  Such knowledge may lead to the development of more specific and 
effective therapies, particularly for patients that are currently at the highest risk for 
treatment failure.  Moreover, understanding how these pathways interact may lead to 
better stratification methods for B-ALL.  Such methods could then be used to minimize 
the overtreatment of low-risk patients.  
Chapter 2:  STAT5 drives B-ALL by opposing gene regulation by the pre-BCR-
NFκB-IKAROS tumor suppressor pathway 
Introduction 
Previous studies have suggested that the role of STAT5 in B cell progenitors is 
only to provide a survival signal3,4.  Therefore, STAT5 could be promoting B-ALL by 
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upregulating genes that promote cell survival.  However, this has yet to be tested.  
Moreover, other groups have shown that STAT5 is involved in other processes in 
progenitor B cells such as cell proliferation, the upregulation of Ebf1, the rearrangement 
of distal VH-DJH gene segments, and the suppression of light chain recombination.  
Therefore STAT5 has roles in B cell development other than promoting cell survival that 
could underlie STAT5-driven leukemia. 
Stat5 is required for the initiation of B-ALL that is driven by BCR-ABL, TEL-JAK2, 
and TEL-PDGFRB translocations203–205.   Moreover, high levels of active STAT5 are 
correlated with poor patient survival in BCR-ABL+ B-ALL2. Together these studies 
indicate that STAT5 is important in the initiation and outcome of B-ALL.  However, these 
studies failed to elucidate the mechanism by which STAT5 drives B-ALL.   
BCR-ABL translocations are associated with defects in pre-BCR signaling.  One 
study suggested that defects in the pre-BCR promote B-ALL by limiting pre-BCR 
signaling below a threshold that induces negative selection in BCR-ABL+ B-ALL233.  
However, pre-BCR signaling is also known to promote cell cycle arrest and 
differentiation.  Therefore, pre-BCR signaling can suppress transformation by multiple 
mechanisms and potentially in ways that are not currently understood.  BCR-ABL is 
known to activate many downstream targets of the pre-BCR.  However, these two 
pathways may interact in other ways as well to promote ALL.  For example, how 
downstream targets of BCR-ABL such as STAT5 might interact with pre-BCR signaling 
effectors to regulate target genes in B-ALL is unclear.  
Therefore the mechanisms by which STAT5 activation and defects in pre-BCR 
signaling components contribute to B-ALL are not entirely understood.  In addition, how 
these pathways might interact is also poorly defined.  Therefore, we aimed to determine 
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the mechanisms by which the deregulation of these two pathways promotes the 
development of ALL. 
Methods 
Mice 
Stat5b-CA, Blnk+/-, Prkcb-/-, Xid, Nfkb1-/-, and Bcl2l1 transgenic mice have been 
described previously299–303.  All mice were backcrossed to the C57Bl/6 background with 
the exception of Prkcb-/-.  Mice were housed in specific pathogen-free facilities at the 
University of Minnesota; all animal experiments were approved by the University of 
Minnesota Institutional Animal Care and Use Committee. All Stat5b-CAxBlnk+/-, Stat5b-
CAxXid and Stat5b-CAxPrkcb-/- leukemias were confirmed by flow cytometry to be B-
ALL.  50% of the Stat5b-CAxNfkb1+/- and Stat5b-CAxNfkb1-/- leukemias were B-ALL and 
the other 50% were T-ALL.  Spleen, lymph nodes, and bone marrow were isolated from 
leukemic mice and used for further experiments.  B220+CD19+ lymph node cells were 
isolated using magnetic bead separation (Miltenyi Biotech, Bergisch Gladbach, 
Germany) and used to isolate RNA and DNA.  Purity of B lymphocytes was > 95% as 
assessed by flow cytometry.  Kaplan-Meier survival curves were created using Prism 
software (GraphPad Software, La Jolla, CA). 
Flow cytometry 
Single cell suspensions were stained with fluorescent antibodies: α-IgM (Jackson 
ImmunoResearch; West Grove, PA), α-CD19 (1D3), α-CD45R (RA3-6B2), α-CD127 
(A7R34), α-pre-BCR (SL165, BD Pharmingen, San Diego, CA), α-Igk (187.1, 
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SouthenBiotech, Birmingham, AL), α-Igl (JC5-1, SouthenBiotech, Birmingham, AL).  α-
CD43 (S7, BD Pharmingen), α-Gr-1 (RB6-8C5), and α-Ter119 (TER-119).  All 
antibodies were obtained from eBioscience (San Diego, CA) unless otherwise indicated.  
SA-PerCP-Cy5.5 was used to detect biotinylated antibodies.  For BrdU analysis, mice 
were injected intraperitoneally with 200 µl of 10 mg/ml BrdU (BD Pharmingen) and 
analyzed after 16 hours.  Cells were assayed on a LSRII or Fortessa flow cytometer (BD 
Biosciences, San Diego, CA) and data was analyzed using FlowJo software (Treestar; 
San Carlos, CA). 
Microarray 
Microarray analysis was performed on total RNA extracted from either sorted 
B220+CD19+IgM-CD43lo pre-B cells (C57Bl/6, Stat5b-CA, or Xid) or B220+CD19+ 
leukemic cells from lymph nodes of tumor-bearing mice using an RNeasy kit (Qiagen, 
Valencia, CA).  cRNA probes were synthesized and hybridized to Mouse 430 2.0 arrays 
following Affymetrix protocols and statistical analyses were performed using 
GeneSpringGX 11.0 (Agilent, Santa Clara CA).  Samples were normalized using RMA, 
filtered on expression (20.0-100.0th) percentile, or Affymetrix Microarray Suite 5.0 
(MAS5.0) software.  Significant gene lists were generated using one-way ANOVA with a 
corrected p-value < 0.05 with a 1.5 fold change in gene expression.  Clustering was 
performed using hierarchical clustering on both entities and conditions, using Euclidean 
distance metric and Centroid Linkage rule.  Synergy scores were calculated as 
described previously304.  Briefly, expression values for each probe were averaged across 
sample groups.  Synergy between Stat5b-CA and Xid was calculated as follows: for any 
probe, let a represent the average Stat5b-CA pre-B value, let b represent the average 
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Xid pre-B value and let c represent the average leukemia value.  Values for each probe 
were entered into the formula [(c/a)+(c/b)] for downregulated genes or [(a+b)/c] for 
upregulated genes.  Synergy scores < 0.9 identified cooperation response genes. A list 
of NFκB target genes was obtained from www.nf-kb.org.  We then restricted our analysis 
to those NFκB target gene expressed in WT pre-B cells, which were defined as those 
genes with an expression ≥ 200 in WT pre-B cells by microarray analysis. 
Quantitative real-time PCR 
CD19+Igλ-Igκ-Gr-1-Ter119- cells were isolated from murine bone marrow by magnetic 
column separation (Miltenyi Biotech) and plated at a concentration of 1-2 x 106 cells/ml 
in Opti-MEM + 5% FBS + 1% penicillin/streptomycin.  Cells were cultured for 16 hours at 
37°C and 5% CO2 with or without 10 ng/ml IL7 (Peprotech, Rocky Hill, NJ).  After 
culturing, RNA was isolated from the cells using an RNeasy kit (Qiagen, Venlo, 
Netherlands).  cDNA was synthesized from 2 ng of RNA using a qScript cDNA synthesis 
kit (Quanta Bisciences, Gaithersburg, MD).  Real-time PCR was performed using 
FastStart Universal SYBR Green Master (Roche, Basel, Switzerland). Primer sequences 
were as follows: Nfkb1 (forward: 5’-GGGAGCCTCTAGTGAGAAGAA-3’; reverse: 5’- 
TGTGACCAACTGAACGATAACC-3’), Nfkb2 (forward: 5’-
CTTTCCTTCGAGCTAGCGATG-3’; reverse: 5’-CATTCGGGAGATCTTCAGGTTC-3’), 
Ikaros (forward: 5’-AAGAGCGATGCCACAACTAC-3’; reverse: 5’-
GTCTTCTGCCATCTCGTTGT-3’), Irf4 (forward: 5’-GGAAGCTCATCACAGCTCAT-3’; 
reverse: 5’-	  AACGTGTTCAGGTAACTCGTAG-3’ Hprt primers have been previously 
described128.  Reactions were run on a 7000 Sequence Detection PCR System (Applied 
Biosystems, Foster City, CA).  Amplification conditions were: 50°C for 2 minutes; 95°C 
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for 10 minutes; 40 cycles of 95°C for 15 seconds and 58°C for 60 seconds.  Normalized 
values were calculated as previously described305. 
Chromatin Immunoprecipitation (ChIP) assays 
ChIP-Seq was performed based on previously published protocols120.  Briefly, 
STAT5b-CAxBlnk+/- tumor lymph node single cell suspensions were stimulated with 10 
ng/mL at 37°C for 30 minutes. Cells were immediately fixed in 1% formaldehyde for 10 
minutes at room temperature. Formaldehyde was quenched with 50 mM Glycine. Cells 
were washed twice with PBS and resuspended in 0.5% SDS, 5.6 mM EDTA, 33.4 mM 
Tris, 84 mM NaCl. DNA was sonicated to 200 bp fragments. 1-8x106 (ChIP-qPCR) or 50 
x106 cell (ChIP-Seq) samples were immunoprecipitated overnight with 10 mg (ChIP-
qPCR) or 50 mg (ChIP-Seq) of a-STAT5 (sc-835 x, Santa Cruz Biotechnology, Santa 
Cruz, CA) or isotype control antibody (sc-2027 x, Santa Cruz Biotechnology) and salmon 
sperm DNA blocked protein A agarose bead slurry (EMD Millipore, Billerica, MA). Beads 
were washed twice with each of low salt, high salt, and LiCl2 buffers then three times 
with TE buffer. DNA was eluted with 1% SDS, 0.1 M NaHCO3. NaCl was added to 0.6 M 
final and crosslinks were reversed at 65°C overnight. Tris, pH 8, was added to 40 mM 
final and EDTA, pH 8, to 8.8 mM final. Samples were digested with 0.1 mg/ml Proteinase 
K for 1 hour. DNA was purified with QIAquick PCR purification kit (Qiagen). Replicate 
IKAROS ChIP-seq datasets were produced using cultures of ~5x107 GM12878 cells 
cultured on separate days, essentially as described36.  The following primers were used 
for ChIP-qPCR: Ikaros promoter B (probe: 5’-AGACGAGGGGGAAGACATTTG-3’, 
forward: 5’-GCTTCCCTCCTTCTTTGCATACTTGG-3’, reverse: 5’- 
CGCAGATTCCTCTTCCTCTTCCTCTT-3’), Ikaros intron 5-6 (probe: 5’- 
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CAAAGGCATTATTAGTCCTGTCTGCCTCC-3’, forward: 5’- 
AAAGAATGCCCACCTTCCCTTCCT-3’, reverse: 5’- 
TTCGAGCTAGTGTTCTGGCCATTG-3’), Nfkb1 intron 14-15 (probe: 5’- 
CTCCAGAAGACAGGTTTCCTTCCTGT-3’, forward: 5’- 
GGGCAATTCTAGGTACAGGAAG-3’, reverse: 5’- ACTCAGAGGAGATGCTGACT-3’), 
Irf4 promoter (probe: 5’-ACCAGGGCTCTGACAATGGAAA-3’, forward: 5’- 
CTTTGAACGAAACTCTGTTGTTTAC-3’, reverse: 5’-GGATGCCATGTCGTTCTTTC-3’), 
Irf8 promoter (probe: 5’-TTCAGAGAAGGCGGATTTGGCAGG-3’, forward: 5’- 
AGTGATTTCTCGGAAAGAGAGC-3’, reverse: 5’-GCGCGAGCTAATTGAGGA-3’), 
Aiolos intron 6-7 (probe: 5’-TGGCCTTCAACCTGATTCTTCAGTGT-3’, forward: 5’- 
TGGTCATCCTTCCTCCTATCC-3’, reverse: 5’-GACTGCTTCCCGCTATACAAG-3’). 
 
Library Preparation 
ChIP-seq libraries were prepared using the Illumina TruSeq ChIP sample kit according 
to the manufacturer’s instructions with the following deviations.  Adaptors were ligated to 
the sample DNA and libraries were PCR amplified prior to size-selection. 
Retroviral transduction 
pMIGR retroviral plasmids containing either nothing, Ikaros, or Stat5b-CA cDNAs 
were transfected into 293 T cells along with helper viruses using Effectene (Qiagen). 
Supernatants were harvested 24-48 hours later and used to transduce Ba/F3 pro-B cells 
(ATCC, Manassas, VA) in the presence of 20% WeHi 3B cell supernatant as previously 
described306. 
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Luciferase Constructs 
Forward (5’-ATTAGAGCTCTGGTGACCGGGATAGTT-3’) and reverse (5’-
ATTACTCGAGAAAGAGGAACTTTATAGAGCCG-3’) primers were used to amplify a 
1372 bp amplicon of the Irf4 promoter. The resulting product was then digested with 
SacI and XhoI (New England Biolabs, Ipswich, MA) and ligated to pGL4.10 (Promega, 
Madison, WI).  Forward (5’-ATTAGCTAGCCTGTCTGGGAGCTGACTATCT-3’) and 
reverse (5’-ATTAAAGCTTGGCTCGAGAGTCGGAGTT-3’) primers were used to amplify 
a 930 bp amplicon of the Cish promoter. The resulting product was then digested with 
NheI and HindIII (New England Biolabs, Ipswich, MA) and ligated to pGL4.10.  Two 
consecutive rounds of site-directed mutagenesis (round 1: 5’- 
CTCCCGCCCAGTTTTCTTTGAAAGTTCTTTGAAATCTGTCAAAGG-3’ and 5’- 
CCTTTGACAGATTTCAAAGAACTTTCAAAGAAAACTGGGCGGGAG-3’; round 2: 5’- 
CGCGGTTCTATGAAGATGAGGCTTCTTTGAAGGGCTGGGACGCAG-3’ and 5’- 
CTGCGTCCCAGCCCTTCAAAGAAGCCTCATCTTCATAGAACCGCG-3’) on the Cish 
pGL4.10 construct were used to generate the Cish pGL4.10 with the IKAROS sites 
mutated. 
Luciferase Assay 
For Irf4 luciferase assays, empty pMIGR or Stat5b-CA Ba/F3 cells were transfected with 
Irf4 promoter pGL4.10 or basic (empty) pGL4.10 and pRL-TK (Promega) by 
electroporation (240 volts, 25 milliseconds).  For Cish lucifierase assays, Ba/F3 cells 
were transfected with a WT or mutated Cish promoter pGL4.10, pRL-TK (Promega), and 
empty, Stat5b-CA, or STAT5b-CA + Ikaros pMIGR constructs by electroporation.  
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Relative light units were measured 48 hours post-transfection using Dual-Luciferase 
Reporter Assay System (Promega). 
Reverse phase proteomics 
This study used samples collected from the blood and/or bone marrow of ALL patients.  
Samples were collected for the Leukemia Sample Bank at the University of Texas M.D. 
Anderson Cancer Center between 1992 and 2007. These samples were collected on 
institutional review board (IRB)–approved protocol Lab01-473, and consent was 
obtained in accordance with the Declaration of Helsinki. Samples were analyzed under 
an IRB-approved laboratory protocol (Lab05-0654). These samples were analyzed using 
reverse phase protein arrays, as previously described307. 
IKAROS deletion detection 
IKAROS deletions in human leukemia samples were detected using the SALSA P335 
ALL-IKAROS Multiplex Ligation-dependent Probe Amplification (MLPA) assay (MRC-
Holland) according to manufacturer’s instructions. 
Mouse STAT5 ChIP-seq analysis 
Mouse STAT5 and input control ChIP-Seq data were mapped to human genome version 
hg19 using BWA v0.7.4308. Duplicate reads were removed using Picard MarkDuplicates 
v1.68 (http://picard.sourceforge.net), and reads with mapping quality less than 1 were 
discarded. MACS v2 was employed for ChIP-seq peak determination309. For ChIP-seq 
distribution plots, identified peaks for each sample are centered by peak summit and 
logarithm normalized average coverage in units of number of reads per million 
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sequenced reads was counted within 3kbp relative to the peak center. The heatmap 
related to Fig. 3f for peak enrichment of different transcription factors with input was 
generated using python-based script on raw reads and visualized +/- 3kbp centered on 
each STAT5 peak summit.  
Mouse IKAROS ChIP-seq analysis 
IKAROS pro-B cell gene expression data and B cell ChIP-seq data (HA-tagged B3 cell 
line and Primary B cell) were retrieved from Ferreirós-Vidal, I., et al.187  HA-tagged B3 
cell line ChIP-seq data were reanalyzed for consistency with the STAT5 ChIP-seq data 
presented here.  Reads were mapped using BWA (v. 0.7.4)308.  Reads with a mapQ >1 
were used to call peaks with MACS2 using default settings (q=0.05). For the IKAROS 
data, for each treatment, (HA-tag, IKAROS IP of Primary B cells), MACS2 was run with a 
p-value cutoff of 0.01, and then the Irreducible Discovery Rate (IDR) procedure310 was 
used to compare the two replicates within each treatment (IDR threshold of 0.01).  This 
resulted in two final lists of genes, one for the HA-tagged treatment, one for the IKAROS 
IP of primary B cells treatment. The high confidence peaks selected from the IDR 
analysis for the two treatments were compared, and overlapping peaks were merged to 
create a final set 5,085 of high confidence, non-overlapping peaks.   
Human IKAROS, NFkB and STAT5A GM12878 ChIP-seq analysis 
Peaks of these ChIP-seq datasets were obtained from the ENCODE consortium 
(encodeproject.org) and were generated by the Transcription Factor ChIP-seq uniform 
processing pipeline developed for the ENCODE Integrative Analysis311. 
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PAX5, EBF, PU.1, IRF4 ChIP-seq analysis 
Published ChIP-seq data for PAX5, EBF, PU.1, and IRF4 in progenitor B cells were 
retrieved from the GEO database (PU.1, EBF, IRF4: GSE53595; PAX5: 
GSE38046)37,312.  Reads were mapped with BWA v.0.7.4308, and reads with a mapQ<1 
were discarded.  Peaks were called with a p-value cut-off of 10-10 and without a matched 
control. 
Gene annotation of ChIP-seq data 
ChIP-seq peaks for all datasets were annotated by selecting all RefSeq genes within +/-
10kb of each peak using bedtools annotate v 2.17.0313.  
Known motif search 
We identified 5,908 STAT5 binding sites (peaks) and scanned over-represented 
transcription factor-binding site motifs from the TRANSFAC database using Pscan-
ChIP314 from those peak regions.  Identified motifs were ranked by local enrichment P-
value. 
Motif scanning analysis 
For the motif scanning analysis, STAT5 motifs were centered and 100 bp of DNA 
sequence 5’ and 3’ were analyzed for the c-REL motif.  Matched motif hits were counted 
at each nucleotide position and then plotted using a histogram, with breaks set at 200. 
Super-enhancer analysis 
Enhancers identified in pro-B cells by Whyte et al.234 were re-scored using STAT5 signal 
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from the present study using ROSE: Rank Order of super-enhancers234,235.  Tag 
enrichment for STAT5, PAX5, EBF, PU.1, IRF4, and IKAROS were generated from 
mapped reads (bams) using ngs.plot.r315.  Annotated super-enhancers in Figure 3 and 
Extended Data Figures 3, 4, and 5 were defined by Whyte et al.234 based on binding of 
Mediator in pro-B cells.  Enhancers in the GM12878 cell line were identified by H3K27-
acetylation and then scored using STAT5 signal using ROSE as described above. 
Venn diagrams 
Peak overlaps for Venn diagrams were generated using bedtools313 to merge the set of 
all peaks for all datasets being compared; peaks from each dataset were then compared 
back to the merged dataset using bedtools intersect. We then counted how many 
merged peaks overlapped with peaks in all of the original datasets, as well as each 
combination of datasets, in order to generate the counts used to create the Venn 
diagrams. Venn diagrams were generated in python using the python package 
matplotlib316 for 2- and 3-way Venn diagrams or using the Vennerable R package 
[https://r-forge.r-project.org/projects/vennerable/] for 4-way Venn diagrams.  
Statistics 
p-values in Kaplan-Meier curves for mouse studies were determined by log-rank Mantle-
Cox test. Similar results were obtained with a Gehan-Breslow-Wilcoxon test (p-values ≤ 
0.0078 in all cases).  A log-rank test for trend of medians was also done for the STAT5b-
CA x Nfkb1+/-,-/- Kaplan-Meier curves; this test demonstrated a significant decrease in 
median survival as Nfkb1 gene dosage decreased (p = 0.0001). The p-values for qRT-
PCR, ChIP-qPCR, luciferase assays, or the quantitation of microarray data were 
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determined by one-way ANOVA with Bonferroni’s multiple comparison post-test; 
*=p≤0.05, **=p≤0.01, ***=p≤0.001, n.s.=not significant; Bars represent mean ± SEM.  
For the human studies evaluating the role of pSTAT5 and IKAROS status, 
human patient samples were first split into two groups based on IKAROS deletion status 
(either WT or IKAROS deleted).  Each of these subgroups was then divided in half again 
based on pSTAT5 levels.  We then merged the two groups with one bad indicator (either 
deleted IKAROS with low pSTAT5 or high pSTAT5 with WT IKAROS).  p-value shown in 
the figure represents log rank test for trend of medians and indicates that median 
survival or remission duration decreases as number of bad indicators increases. p-
values from log-rank Mantle-Cox test and Gehan-Breslow-Wilcoxon test for survival 
were also calculated and were 0.0016 and 0.0036, respectively; for remission duration 
these p-values were 0.0022 and 0.0027, respectively.  A similar analysis was carried out 
in the human studies evaluating the role of pSTAT5 and RELA, except samples were 
first split into two groups based on the pSTAT5/RELA ratio (low versus high).  These two 
groups were then split into two groups again based on total pSTAT5 levels within each 
group.  We then merged the two groups with one bad indicator (high pSTAT5/RELA with 
low pSTAT5 or low pSTAT5/RELA with high pSTAT5). P-value shown represents log 
rank test for trend of medians.  P-values for log-rank Mantle-Cox test and Gehan-
Breslow-Wilcoxon test were also calculated and were 0.0792 and 0.0636, respectively.  
All calculations were carried out using Prism software. 
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Results 
Stat5b-CA mice develop spontaneous B-ALL with low penetrance 
In order study the role of STAT5 in B-ALL, we utilized transgenic mice that 
express a constitutively active form of STAT5b throughout B cell development (Stat5b-
CA mice)299.  In this model, STAT5b has been rendered constitutively active by replacing 
histidine 299 and serine 711 with arginine and phenylalanine, respectively299,317.  
Mutation of STAT5b in this manner results in the constitutive phosphorylation of tyrosine 
699, thereby mimicking the process by which wild-type (WT) STAT5 is activated299,317.  
The expression of this transgene is restricted to B and T cells by a compound promoter 
and enhancer cassette consisting of the Lck proximal promoter and the Eµ enhancer299. 
Approximately 1-2% of Stat5b-CA mice spontaneously develop leukemia132,299.  
To better characterize these leukemias, we preformed flow cytometry on the leukemic 
cells from Stat5b-CA mice.  This analysis revealed that Stat5b-CA leukemias 
phenotypically appear to be transformed pre-B cells based on the expression pattern of 
CD19, IL7Rα, pre-BCR, CD43, and BP-1 (Figure 2.1a).  Therefore, the leukemia 
observed in Stat5b-CA mice resembles B-ALL.  The leukemic pre-B cells can be found 
in the blood, spleen, lymph nodes, and bone marrow (Figure 2.1b).  
To determine whether these leukemias are clonal, we assessed immunoglobulin 
heavy chain gene rearrangements by PCR amplification with primers specific for various 
distal and proximal VH gene loci (Figure 2.1c).  B220+CD19+ leukemic lymph node cells 
from one Stat5b-CA mouse indicated usage of primarily the VHQ52 and JH2 gene 
segments, while leukemic cells from another mouse were limited to VHJ558-DJH1 
rearrangements.  Based on these patterns of gene rearrangement, Stat5b-CA leukemias 
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appear to be clonal, suggesting that they arise from a single transformed B cell 
progenitor. 
The low penetrance and clonality of Stat5b-CA leukemias suggests that active 
STAT5 requires secondary mutations to cause disease.  Therefore, we preformed 
microarray analysis to identify potential genes and pathways that are deregulated in 
these leukemias.  As compared to WT pre-B cells, Stat5b-CA leukemias exhibit 
decreased expression of genes involved in pre-BCR signaling, including Vpreb1, Igll1 
(λ5), Blk, Sykb (SYK), and Prkcb (PKCβ) (Figure 2.1d).  This suggested that loss of pre-
BCR signaling was an important step in the initiation of STAT5-dependent leukemia, and 
lead us to hypothesize that STAT5 activation cooperates with defects in pre-BCR 
signaling components to initiate B-ALL.  
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Figure 2.1. Spontaneous leukemia in Stat5b-CA mice.   
a, (Left 3 panels) Flow cytometric analysis of total cells from leukemic Stat5b-CA lymph 
nodes or total lymphocytes from WT C57BL/6 bone marrow (dot-plot).  (Right panels) 
Flow cytometric analysis of B220+ lymphocytes from leukemic Stat5b-CA lymph nodes 
or B220+ lymphocytes from WT C57BL/6 bone marrow.  b, (Upper panel) Photo of a 
Stat5b-CA mouse that developed ALL-like leukemia.  (Lower panel) Spleen from a 
leukemic Stat5b-CA mouse compared to an age-matched WT C57Bl/6 control.  c, 
Clonality as determined by Igh gene usage. Stat5b-CA refers to B220+CD19+ leukemic 
lymph node cells from Stat5b-CA mice; WT refers to CD19+ splenic B cells from C57Bl/6 
mice.  Wedges above lanes represent serial dilutions of 100, 10, and 1 ng of genomic 
DNA.  DNA was amplified using primers specific for VHJ558-DJH, VHQ52-DJH, and 
VH7183-DJH rearrangements and detected by Southern blotting.  Numbers on right 
indicate rearrangements involving different JH segments.  PCR with Actin-specific 
primers was used as a loading control.  Results are representative of 4 experiments.  d, 
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mRNA expression in Stat5b-CA leukemias as determined by microarray analysis.  RNA 
was isolated from CD19+B220+ leukemic lymph node cells (n = 6) or sorted pre-B cells 
from WT C57BL/6 bone marrow (B220+CD19+IgM-CD43-; n = 5).  Asterisks indicate 
genes involved in pre-BCR signaling. 
Active STAT5 cooperates with defects in pre-BCR signaling components to initiate 
B-ALL 
To test our hypothesis, we bred the Stat5b-CA mice to mice that harbor loss-of-
function mutations in the pre-BCR adaptor Blnk, or the downstream kinases Btk (Xid 
mutant) or Prkcb.  The resulting Stat5b-CA x Blnk+/-, Stat5b-CA x Xid and Stat5b-CA x 
Prkcb-/- mice rapidly developed leukemia with high frequency (Figure 2.2a).  In contrast, 
Blnk+/-, Xid and Prkcb-/- control mice never developed leukemia.  Similar to Stat5b-CA 
leukemias, Stat5b-CAxBlnk+/-, Stat5b-CAxXid and Stat5b-CAxPrkcb-/- leukemias 
resemble pre-B cell leukemia based on the expression of B220, IL7Rα and pre-BCR 
(Figure 2.2a).  These leukemias express intermediate levels of µH chain, but this is likely 
pairing with the surrogate late chain as Stat5b-CA x Blnk-/- leukemias do not express Igκ 
or Igλ (Figure 2.2b,c).   Therefore the Stat5b-CA x Blnk+/-, Stat5b-CA x Xid and Stat5b-
CA x Prkcb-/- mice develop highly penetrant forms of leukemia that resemble B-ALL.  
This confirmed our initial hypothesis that STAT5 activation cooperates with defects in 
pre-BCR signaling components to initiate leukemia. 
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Figure 2.2. Loss of pre-BCR signaling components cooperates with STAT5b-CA to 
induce pre-B ALL.   
a, (Left panels) Survival of Stat5b-CA x Blnk+/-, Stat5b-CA x Xid, and Stat5b-CA x Prkcb-/- 
mice compared to littermate controls.  Deaths are indicative of leukemia development.  
(Right panels) Flow cytometric analysis of B220, IgM, IL7R, and pre-BCR expression on 
lymph node cells from Stat5b-CA x Blnk+/-, Stat5b-CA x Xid, and Stat5b-CA x Prkcb-/- 
leukemic mice.  Grey histograms represent staining for these markers on mature B220+ 
B cells from lymph nodes of C57Bl/6 mice.  b, (Left 3 panels) Flow cytometric analysis of 
total cells from leukemic Stat5b-CA x Blnk-/- lymph nodes or total lymphocytes from WT 
C57BL/6 bone marrow.  (Right panel) Flow cytometric analysis of total cells from 
leukemic Stat5b-CA x Blnk-/- lymph nodes (dot-plot). 
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STAT5 does not drive B-ALL by solely promoting cell survival or proliferation 
We next tested whether STAT5 drives transformation solely by providing survival 
signals.  To do this, we bred Blnk+/- mice with transgenic Bcl2l1 (i.e., Bcl-XL) mice300.  
Bcl2l1 transgenic mice exhibit a comparable expansion of progenitor B cells as seen in 
Stat5b-CA mice299,300.  Unlike STAT5b-CA, however, BCL-XL overexpression did not 
cooperate with Blnk+/- to initiate leukemia (Figure 2.3a).   We then used BrdU labeling to 
test if STAT5 could be driving transformation by enhancing cell division.  However, these 
experiments revealed that Stat5b-CA x Xid leukemias do not proliferate significantly 
more than WT or Xid pre-B cells (Figure 2.3b).  Therefore, STAT5 does not induce 
leukemia by solely promoting survival or enhancing the proliferation of progenitor B cells. 
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Figure 2.3. STAT5 does not drive leukemia by solely promoting cell survival or -
proliferation.   
a, Survival of Blnk+/- x Bcl-xL compared to Stat5b-CA x Blnk+/- mice.  Deaths are 
indicative of leukemia development.  b, BrdU analysis of pre-B cell proliferation.  (Left 
panel) Representative histogram of BrdU levels in B220midCD19+CD25+ pre-B cells from 
Stat5b-CA x Xid leukemic mice compared to WT C57Bl/6 and Xid non-leukemic controls.  
(Right panel) Percentage of BrdU+ pre-B cells in each group of mice.  Differences 
between groups were not significant as determined by one-way ANOVA (p = 0.19).  
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STAT5 antagonizes NFκB regulation of NFκB target genes 
We next sought to find other signaling effectors downstream of the BLNK-BTK-
PKCβ pathway that are important in suppressing STAT5-driven leukemia.  One protein 
that is activated by this pathway is the transcription factor NFκB60,90,142,147,223.  Microarray 
analysis revealed that the expression of 67 NFκB target genes was altered in Stat5b-CA 
x Blnk+/-, Stat5b-CA x Xid and Stat5b-CA x Prkcb-/- leukemias compared to WT pre-B 
cells (Figure 2.4a).  In addition, the expression of more than 50 of these NFκB target 
genes was changed in Stat5b-CA pre-B cells compared to WT pre-B cells, suggesting 
that STAT5 regulates dozens of NFκB targets (Figure 2.4b,c).  We then used an 
algorithm developed by Land and colleagues304 to show that STAT5 activation 
synergized with decreased pre-BCR signaling to modulate the expression of 25 NFκB 
target genes, including the oncogenes Bcl2, Ccnd2 and Myc (Figure 2.4d).  Therefore, 
STAT5 antagonizes the regulation of several NFκB target genes by a pre-BCR signaling 
pathway involving BLNK, BTK, and PKCβ.  
We next tested whether STAT5 can regulate the expression of NFκB targets 
directly.  To do this, we performed a chromatin immunoprecipitation followed by next 
generation sequencing (ChIP-Seq) on STAT5 in Stat5b-CA x Blnk+/- leukemias.  This 
analysis showed that STAT5 bound to ~50% of the NFκB target genes that are 
deregulated in the Stat5b-CA x Blnk+/-, Stat5b-CA x Xid and Stat5b-CA x Prkcb-/- 
leukemias compared to WT pre-B cells (Figure 2.5a,b).  Moreover, the STAT5 binding 
sites identified by ChIP-Seq showed an enrichment for nearby NFκB binding motifs, 
suggesting that STAT5 and NFκB share binding sites at numerous loci (Figure 2.5c,d, 
Table 2.1).  We then confirmed that STAT5 binds to the NFκB targets Irf4 and Irf8 by 
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ChIP-qPCR (Figure 2.5e).  In addition, qRT-PCR of WT pre-B cell transcripts suggests 
that IL7 stimulation decreases the expression of Irf4 (Figure 2.5f).  Furthermore, a trend 
from luciferase assays suggests that STAT5 can repress transcription by binding to the 
Irf4 promoter, although this is not statistically significant (Figure 2.5g,h).   Together, 
these data suggest that STAT5 directly regulates several NFκB target genes including 
the tumor suppressors Irf4 and Irf8318.  
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Figure 2.4. STAT5 opposes pre-BCR regulation of NFkB target genes.   
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a, Microarray analysis of mRNA expression of NFkB targets in pre-B cells or B-ALL-like 
leukemias. Heatmap represents genes with significantly altered expression compared to 
WT C57Bl/6 pre-B cells in both RMA- and MAS5.0-transformed sets.  b, Venn diagrams 
of NFκB target genes that have reduced expression in Stat5b-CA x Prkcb-/- leukemias 
(top panel) or Stat5b-CA x Blnk+/- leukemias (bottom panel) compared to WT C57BL/6 
pre-B cells.  NFκB target genes that also exhibit reduced expression in Stat5b-CA pre-B 
cells compared to WT pre-B cells or B-ALL-like leukemias compared to Stat5b-CA pre-B 
cells are shown as well.  Percentages indicate the fraction each gene subset comprises 
of all NFκB target genes that are reduced in the B-ALL-like leukemias compared to WT 
pre-B cells.  c, mRNA expression by microarray analysis of NFκB target genes with 
reduced expression in Stat5b-CA pre-B cells compared to WT pre-B cells and further 
reduced expression in Stat5b-CA x Prkcb-/- leukemias compared to Stat5b-CA pre-B 
cells.  d, Synergistic effects of STAT5b-CA and loss of pre-BCR signaling on NFκB 
target gene expression.  Genes identified in panel a were used to calculate synergy 
scores (see Methods).  Heatmap represents mRNA expression of genes with synergy 
scores < 0.9. 
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Figure 2.5. STAT5 opposes pre-BCR regulation of NFkB target genes.   
a, Venn diagram illustrating overlap of STAT5-bound genes in Stat5b-CAxBlnk+/- 
leukemia with NFκB gene targets and genes deregulated in Stat5b-CAxBlnk+/-, Stat5b-
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CAxXid, and Stat5b-CAxPrkcb-/- leukemias. b, STAT5 occupancy in Stat5b-CAxBlnk+/- 
leukemias at select NFκB target genes by ChIP-seq. c, Transcription factor binding 
motifs enriched by STAT5 ChIP-Seq in Stat5b-CAxBlnk+/- leukemias. d, Distribution of c-
REL binding motifs relative to STAT5 binding sites found by STAT5 ChIP-Seq.  e, 
STAT5 ChIP followed by quantitative PCR (ChIP-qPCR) at Irf4 promoter (left panel) or 
Irf8 promoter (right panel) in Stat5b-CAxBlnk+/- leukemias.  f, Quantitative real-time PCR 
for Irf4 expression in WT pre-B cells.  g, Luciferase activity of Irf4 promoter in Ba/F3 pro-
B cells transfected with empty or Stat5b-CA pMIGR retroviruses.  Relative luciferase 
activity is calculated as the relative firefly/renilla activity of the Irf4 luciferase construct 
divided by the relative firefly/renilla activity of an empty luciferase construct with no 
promoter.  Paired t-test p-value = 0.23.  h, Illustration of the WT Irf4 luciferase construct. 
STAT5 binding sites are underlined in red.  Base pair (bp) positions indicate distances 
relative to the Irf4 transcriptional start codon.	  	  Results (e left panel, g) represent three 
independent experiments; results (e right panel) represent two independent 
experiments; results (f) represent duplicates from one experiment. 
 
STAT5 represses the expression of Nfkb 
In addition to regulating NFκB target genes, we investigated whether STAT5 can 
directly regulate Nfkb.  ChIP-seq analysis revealed that STAT5 bound to Nfkb1 and 
Nfkb2 (Figure 2.6a,b).  Moreover, WT pre-B cells express less Nfkb1 following IL7 
stimulation, and Stat5b-CA pre-B cells express less Nfkb2 compared to WT pre-B cells 
following stimulation with IL7 (Figure 2.6c).  Therefore STAT5 binds to and represses the 
expression of Nfkb2.  STAT5 also binds to and likely negatively regulates Nfkb1 
expression in a similar fashion. 
	  	   65	  
0 100 200 300 400
0
25
50
75
100
p < 0.0001
Stat5b-CA
x Nfkb1-/-
Stat5b-CA
x Nfkb1+/-
(n = 23)
Nfkb1+/-, -/-
Age (days)
0.0
0.5
1.0
WT
R
el
at
iv
e 
N
fk
b2
 
m
R
N
A
 e
xp
re
ss
io
n
Unstimulated
IL7
Stat5b-CA
S
ur
vi
va
l (
%
)
***
10 kb
Nfkb1
2 kb
Nfkb2
(n = 27)
(n = 27)
b
a
c
d
0.00
0.05
0.10
0.15
0.20
-STAT5 IsotypeIP:
N
fk
b1
 in
tro
n 
14
-1
5
%
 o
f I
np
ut
* *
Unstimulated
IL7
STAT5
0.0
0.5
1.0
R
el
at
iv
e 
N
fk
b1
 
m
R
N
A
 e
xp
re
ss
io
n
WT 	  
Figure 2.6. STAT5 binds to and represses the expression of the tumor suppressor 
Nfkb.   
a, STAT5 occupancy in Stat5b-CAxBlnk+/- leukemias at Nfkb1 and Nfkb2 by ChIP-seq. 
b, STAT5 ChIP followed by quantitative PCR (ChIP-qPCR) at Nfkb1 intron 14-15 in 
Stat5b-CAxBlnk+/- leukemias.  c, Quantitative real-time PCR for Nfkb1 and Nfkb2 
expression in WT or Stat5b-CA pre-B cells.  d, Survival of Stat5b-CAxNfkb1+/- and 
Stat5b-CAxNfkb1-/- mice.  Results (b and c right panel) represent three independent 
experiments; results (c left panel) represent duplicates from one experiment. 
 
Active STAT5 cooperates with loss of Nfkb1 to initiate B-ALL 
We next tested if the interaction between STAT5 and NFκB is important in 
leukemogenesis by breeding Stat5b-CA mice with Nfkb1-/- mice.  The resulting crosses, 
Stat5b-CA x Nfkb1+/- and Stat5b-CA x Nfkb1-/- mice, developed leukemia at a high 
frequency (Figure 2.6d).  However, Nfkb1+/- and Nfkb1-/- control mice did not develop 
ALL.  Thus, NFκB1 functions as a tumor suppressor in pre-B cells to oppose STAT5-
dependent pre-B cell leukemia.  Conversely, STAT5 antagonizes the transcription of 
Nfkb2 and multiple NFκB target genes.  
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STAT5 and IKAROS opposingly regulate hundreds of shared target genes 
NFκB promotes the expression of the transcription factor Ikaros by upregulating 
IRF4 and IRF896,147,148.  Our ChIP-seq analysis revealed that IKAROS binding motifs 
were enriched near STAT5 binding sites in the Stat5b-CA x Blnk+/- leukemias (Figure 
2.5c).  Furthermore, comparison of our STAT5 ChIP-Seq dataset with an IKAROS ChIP-
Seq dataset in pre-B cells187 showed that 37% of genes bound by IKAROS were also 
bound by STAT5.  Moreover, 53% of these genes (896 in total) show direct binding 
overlap between IKAROS and STAT5 (Figures 2.7a,b, 2.8).  This included 249 genes 
that are bound and regulated by IKAROS in pre-B cells and deregulated in the Stat5b-
CA x Blnk+/-, Stat5b-CA x Xid and Stat5b-CA x Prkcb-/- leukemias (Figure 2.7b).  Of those 
249 genes, 180 (72%) show reciprocal regulation by STAT5 and IKAROS.  This 
suggests that STAT5 and IKAROS share hundreds of direct target genes, and that these 
transcription factors tend to oppose the regulation of one another.  Moreover, because 
STAT5 and IKAROS binding appears to directly overlap at numerous loci by ChIP-seq, 
this therefore suggests that these transcription factors can potentially compete for 
binding to target genes.   
In order to test this possibility, we cloned the promoter of a shared target gene, 
Cish, into a luciferase reporter construct.  Importantly, the STAT5 and IKAROS binding 
sites overlap at a sequence level in this promoter123,127 (Figure 2.9a,c).  The ectopic 
expression of STAT5b-CA induced luciferase activity in a pro-B cell line, while co-
expression of STAT5b-CA and IKAROS reduced this effect.  Conversely, transfection 
with a Cish lucifierase reporter with mutated IKAROS binding sites alleviated the 
repression by IKAROS (Figure 2.9b,c).  Therefore, this suggests that STAT5 and 
IKAROS can antagonize each other by competing for the binding to target genes.  
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Figure 2.7. STAT5 and IKAROS bind and regulate hundreds of shared target 
genes.   
a, Distribution of STAT5 and IKAROS peak summits relative to STAT5 binding sites by 
ChIP-Seq.  b, Venn diagram of genes deregulated in Stat5b-CAxBlnk+/-, Stat5b-CAxXid, 
and Stat5b-CAxPrkcb-/- leukemias compared to WT pre-B cells; genes bound by STAT5 
in Stat5b-CAxBlnk+/- leukemias; genes bound by IKAROS in pre-B cells; genes regulated 
by IKAROS. 
 
 
	  	   68	  
STAT5
IKAROS
PAX5
EBF
PU.1
IRF4
5 kb
SE
Bcl2l1
1 kb
Vpreb1Igll1
SE
5 kb
Ccnd2 Myc
2 kb
5 kb
Bcl6
SE
10 kb
Ccnd3
SE SE
	  
Figure 2.8. STAT5 binding overlaps with the binding PAX5, EBF1, PU.1, IRF4, and 
IKAROS at genes that promote pre-B cell survival, proliferation, and 
differentiation.   
Occupancy of STAT5, PAX5, EBF, PU.1, IRF4 and IKAROS by ChIP-Seq at Bcl2l1 
(BCL-XL), Igll1 (λ5), Vpreb1, Ccnd2, Ccnd3, Bcl6, and Myc loci; SE = super-enhancer. 
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Figure 2.9. STAT5 and IKAROS reciprocally regulate Cish by binding to 
overlapping binding sites in the Cish promoter.   
a, Occupancy of STAT5, PAX5, EBF, PU.1, IRF4 and IKAROS by ChIP-Seq at the Cish 
locus.  b, Luciferase activity of WT or mutant Cish promoter in Ba/F3 pro-B cells 
transfected with empty, Stat5b-CA, or Stat5b-CA and Ikzf1 pMIGR retroviruses.  c,	  
Illustration of the WT and mutant Cish luciferase constructs. STAT5 and IKAROS 
binding sites are underlined.  Mutated base pairs are indicated with asterisks.  Base pair 
(bp) positions indicate distances relative to the Cish translational start codon. Results (b) 
represent three independent experiments. 
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STAT5 represses Ikaros and Aiolos expression 
We next investigated whether STAT5 can repress the expression of Ikaros 
directly.  We found that STAT5 binds to a promoter of Ikaros (promoter B), which is 
known to drive the expression of Ikaros in the B lineage specifically319,320 (Figure 
2.10a,b).  Moreover, qRT-PCR analysis revealed that Ikaros transcripts are reduced in 
Stat5b-CA pre-B cells compared to WT pre-B cells (Figure 2.10c).  These data therefore 
suggest that STAT5 can directly bind to and repress Ikaros expression.  We found that 
STAT5 similarly binds to and represses the expression of the related Ikaros family 
member, Aiolos (Figure 2.10a,d).  Therefore, STAT5 opposes IKAROS function by 
multiple mechanisms.  STAT5 opposes target gene regulation by IKAROS, potentially by 
competing for binding to shared target gene loci and by non-competitive mechanisms 
involving the binding to non-overlapping binding sites within shared target genes.  In 
addition, STAT5 can also oppose IKAROS function by binding to and repressing the 
expression of the Ikaros family members Ikaros and Aiolos. 
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Figure 2.10. STAT5 binds to and represses the expression of Ikaros and Aiolos.  
a, STAT5 occupancy (red) in Stat5b-CA x Blnk+/- leukemias at Ikaros or Aiolos loci by 
ChIP-seq. The two arrows in Ikaros indicate two alternative transcriptional start sites 
near promoters A and B; SE = super-enhancer. b, STAT5 ChIP followed by quantitative 
PCR (ChIP-qPCR) at Ikaros promoter B (left panel), Aiolos intron 6-7 (middle panel), or 
Ikaros intron 5-6 (middle panel) in Stat5b-CAxBlnk+/- leukemias.  c, STAT5 ChIP-qPCR 
at Ikaros promoter B in WT C57BL/6 pre-B cells.  d, Quantitative real-time PCR for 
Ikaros expression in WT or Stat5b-CA pre-B cells.  e, The expression of Aiolos 
transcripts by microarray analysis in WT pre-B cells, Stat5b-CA pre-B cells, Stat5b-CA x 
Blnk+/- leukemias, or Stat5b-CA x Prkcb-/- leukemias.  Results (left and right panels in b, 
c, d, e) represent at least three independent experiments.  Results (middle panel in b) 
represent two independent experiments. 
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Active STAT5 cooperates with loss of Ikaros to promote ALL 
We next tested whether constitutively active STAT5 can cooperate with loss of 
function mutations in Ikaros to drive B-ALL.  However, the resulting Stat5b-CA x Ikaros+/- 
mice developed T cell leukemia rather than pre-B cell leukemia (data not shown).  To 
circumvent this issue, we used a sleeping beauty (SB) transposon mutagenesis screen 
to identify genes that cooperate with Stat5b-CA to initiate B-ALL.  The transposon 
contains two splice acceptors and a bi-directional poly(A) and can terminate transcription 
when integrated in either orientation in a gene321.  It also contains a murine stem cell 
virus (MSCV) promoter that can promote gene expression when integrated upstream or 
within a gene321.  The position and orientation of the MSCV promoter relative to the 
direction of normal gene transcription can be used to predict whether the transposon is 
likely to drive or disrupt gene transcription322.  We restricted the expression of the 
transposon to cells of the B-lineage by using Mb1-cre.  The resulting leukemias almost 
entirely originated from the B lineage.  Ikaros was identified as a common insertion site 
in this screen, and the orientation and location of the transposon insertions within the 
Ikaros locus were predicted to cause loss of function mutations (L.M.H.H. and M.A.F., 
manuscript in-preparation).  Moreover, Ikaros expression was significantly reduced in 
these T2/onc x Stopfl/fl-Rosa26 x SB1/15 x Mb1-cre x Stat5b-CA leukemias compared to 
WT controls (L.M.H.H. and M.A.F., manuscript in-preparation).  These data suggest that 
STAT5 activation and loss of function mutations in Ikaros cooperate to initiate B-ALL. 
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STAT5 binding overlaps with the binding of PAX5, EBF1, PU.1, IRF4, and IKAROS 
at super-enhancers 
IKAROS forms a transcriptional network with PAX5, EBF1, PU.1, and IRF4 
(referred to as PEPII factors) that regulates B cell differentiation.  Therefore, we 
evaluated whether STAT5 binding also overlapped with the binding of other members of 
this network.  We found enrichment of the binding motifs of all PEPII factors in our 
STAT5 ChIP-Seq dataset (Table 2.1).  Furthermore, comparison of PEPII37,187,312,323 and 
STAT5 ChIP-Seq datasets demonstrated a substantial enrichment of PEPII factors at 
STAT5-bound loci (Figure 2.11a).  In contrast, the transcription factor FOXO1, which 
also supports B cell development, did not overlap significantly with STAT5 binding 
(Figure 2.11a).  Thus, STAT5 binding directly overlaps with the binding of many but not 
all transcription factors that promote B cell differentiation. 
We next evaluated whether STAT5 and the PEPII factors interact with progenitor 
B cell super-enhancers.  We found that 67% of pro-B cell super-enhancers are bound by 
4 or more members of the PEPII network (Figure 2.11b).  Furthermore, 70% of PEPII-
bound super-enhancers are also bound by STAT5 in B-ALL-like leukemia (Figure 2.11b).  
We next identified enhancers that have the highest levels of STAT5 binding by ranking 
pro-B cell enhancers based on the amount of STAT5 bound at each enhancer.  We 
found that high levels of STAT5 were enriched at super-enhancers over typical 
enhancers (Figure 2.11c), suggesting that STAT5 binding levels correlate with super-
enhancer activity in pro-B cells.  Moreover, PEPII factors and high levels of STAT5 
binding were enriched at super-enhancers linked to genes regulating survival, cell cycle, 
and B cell differentiation (Figures 2.8, 2.11c).  Consistent with other super-enhancer 
networks, STAT5 and PEPII factors cross-regulated each other (Figure 2.12).  These 
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data demonstrate that STAT5 participates in a regulatory B cell transcriptional network at 
B cell super-enhancers, and suggest that STAT5 regulation is a defining feature of B-
ALL. 
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Table 2.1. Transcription factor binding motifs enriched by STAT5 ChIP-seq.   
A list of transcription factor binding motifs enriched following a STAT5 ChIP-seq in 
Stat5b-CA x Blnk+/- leukemias.  Motifs were identified using the Transfac (left column) or 
Jaspar (right column) databases. 
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Figure 2.11. STAT5 binding overlaps with the binding of PAX5, EBF1, PU.1, IRF4, 
and IKAROS at pro-B cell super-enhancers.   
a, Heat map of STAT5, PAX5, EBF, PU.1, IRF4, IKAROS and FOXO1 occupancy 
centered on STAT5 binding sites at STAT5-bound loci by ChIP-seq.  Input is a negative 
control for the STAT5 ChIP-seq.  b, Venn-diagram illustrating the peak-level overlap of 
STAT5, 4 or more of PAX5, EBF, PU.1, IRF4, and IKAROS (PEPII), and pro-B cell 
super-enhancers. c, STAT5 ChIP-seq signal in reads-per-billion at pro-B cell enhancers 
and super-enhancers. 
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Figure 2.12. Coordinated binding of STAT5, PAX5, EBF, PU.1, IRF4, and IKAROS at 
genes that govern pre-B cell transcriptional networks.   
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a, Occupancy of STAT5, PAX5, EBF, PU.1, IRF4 and IKAROS by ChIP-Seq at Il7r, 
Jak1, Stat5b, Stat5a and Socs3 loci.  b, Occupancy of STAT5, PAX5, EBF, PU.1, IRF4 
and IKAROS by ChIP-Seq at Pax5, Ebf1, Sfpi, Irf4 and Ikzf1 loci. SE = super-enhancers. 
STAT5, IKAROS, and NFκB binding overlaps in human B cell leukemia 
We then determined if the results we observed in murine leukemias are 
recapitulated in human leukemia.  To test this, we evaluated the binding of STAT5, 
IKAROS, and the NFκB subunit RELA (p65) in a B lymphoblastoid cell line.  This 
analysis revealed that 41% and 33% of STAT5 binding sites overlap with IKAROS or 
RELA binding sites, respectively (Figure 2.13a,b).  In addition, we found that high levels 
of STAT5 binding tend to occur in B cell super-enhancers rather than typical enhancers.  
Moreover, we found that super-enhancers with high levels of STAT5 were enriched for 
associated genes that control survival, proliferation, and B cell differentiation (Figure 
2.13c).  We further confirmed our results in human B-ALL, as we found an enrichment of 
STAT5 binding motifs near IKAROS binding sites that were identified by ChIP-Seq in two 
primary BCR-ABL+ B-ALL samples (Figure 2.13d).  Thus, STAT5 binding overlaps with 
NFκB and IKAROS in transformed human B cells.  Moreover, STAT5 appears to 
regulate a similar network of super-enhancers in mouse and human B cell malignancies.   
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Figure 2.13. STAT5 binding overlaps with NFκB and IKAROS binding and with 
super-enhancers in human B cells.   
a, Venn diagram showing overlap between STAT5, IKAROS and NFκB binding sites by 
ChIP-seq in the GM12878 human B lymphoblastoid cell line.  b, Occupancy of STAT5, 
IKAROS and NFκB at BCL2L1, CCND2 and MYC in GM12878 cells.  c, STAT5 ChIP-
Seq signal in reads-per-billion at pro-B cell enhancers and super-enhancers in GM12878 
cells.  d, Distribution of STAT5 binding motifs relative to IKAROS binding sites found by 
IKAROS ChIP-Seq in ICN1 and LAX2 primary B-ALL samples.   
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The ratio of STAT5 and IKAROS or NFκB correlates with B-ALL patient outcomes 
We next examined whether the interaction between STAT5 and IKAROS is 
clinically significant in B-ALL.  Based on our current findings, we hypothesized that the 
ratio of active STAT5 (pSTAT5) to IKAROS will inversely correlate with remission 
duration and patient survival.  To test this, we subdivided B-ALL samples from a cohort 
of 69 patients into three groups:  (1) low pSTAT5 and WT IKAROS (two good indicators), 
(2) low pSTAT5 and deleted IKAROS (ΔIKAROS) or high pSTAT5 and WT IKAROS (one 
bad indicator) and (3) high pSTAT5 and deleted IKAROS (2 bad indicators).  As 
predicted, we observed a significant decrease in remission duration and patient survival 
as the number of bad prognostic indicators increased (Figures 2.14a, 2.15a).  In 
contrast, IKAROS or pSTAT5 status alone was less effective at predicting survival or 
remission duration (Figures 2.14b-f, 2.15b-f).  Similarly, we examined if the relationship 
of pSTAT5 and RELA correlated with survival in 161 B-ALL patients.  Patient samples 
were split into three groups based on total pSTAT5 levels and the ratio between pSTAT5 
and RELA:  (1) low total pSTAT5 and low pSTAT5/RELA (two good indicators), (2) low 
total pSTAT5 and high pSTAT5/RELA or high overall pSTAT5 and low pSTAT5/RELA 
(one bad indicator) and (3) high overall pSTAT5 and high pSTAT5/RELA (two bad 
indicators).  The combination of high pSTAT5 with a high ratio of pSTAT5 to RELA 
correlated most strongly with decreased survival (Figure 2.16a).  In contrast, pSTAT5 
levels or the ratio of pSTAT5 to RELA alone did not effectively correlate with overall 
patient survival (Figure 2.16b-f).  Thus, the combination of pSTAT5 levels and IKAROS 
deletion status or pSTAT5 levels and the ratio of pSTAT5 to RELA strongly correlated 
with patient outcomes. 
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Our patient cohorts in the aforementioned studies included BCR-ABL+ ALL 
cases.  Moreover, the BCR-ABL+ cases were disproportionally enriched in the groups 
with two bad prognostic indicators (high pSTAT5 and ΔIKAROS or high pSTAT5/RELA).  
Therefore, the worse outcomes associated with these groups could be due to an 
increased prevalence of BCR-ABL, which has already been shown to be associated with 
poor outcomes.  However, we obtained similar stratifications after removing the BCR-
ABL cases from our analyses (Figures 2.17-2.19).  Therefore, pSTAT5 levels and 
IKAROS deletion status or pSTAT5 levels and the ratio of pSTAT5 to RELA correlate 
with patient survival and remission duration regardless of BCR-ABL status. 
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Figure 2.14. STAT5 activation paired with deletion of IKAROS negatively correlates 
with the survival of B-ALL patients.   
a, Survival of B-ALL patients stratified by pSTAT5 and IKAROS status: WT or deleted 
(Δ). p-values represent log-rank test for trend of medians.  b, Survival of B-ALL patients 
that were stratified based on IKAROS status alone: WT or deleted.  c, Survival of B-ALL 
patients that were separated into two equal-sized groups based on low or high pSTAT5 
levels.  d, e, Survival of B-ALL patients that were stratified by separating them based on 
IKAROS status (WT or deleted) and then further subdividing those groups based 
pSTAT5 levels (low or high).  p-values in panels b-e represent log-rank (Mantel-Cox) 
test. f, Statistical summary of the results shown in panels b-e.  ND = not done. 
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Figure 2.15. STAT5 activation paired with deletion of IKAROS negatively correlates 
with remission duration in B-ALL patients.   
a, Remission duration in B-ALL patients stratified by pSTAT5 and IKAROS status: WT or 
deleted (Δ). p-values represent log-rank test for trend of medians.  b, Remission duration 
in B-ALL patients that were stratified based on IKAROS status alone: WT or deleted.  c, 
Remission duration in B-ALL patients that were separated into two equal-sized groups 
based on low or high pSTAT5 levels.  d, e, Remission duration in B-ALL patients that 
were stratified by separating them based on IKAROS status (WT or deleted) and then 
further subdividing those groups based pSTAT5 levels (low or high). p-values in panels 
b-e represent log-rank (Mantel-Cox) test. f, Statistical summary of the results shown in 
panels b-e.   
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Figure 2.16. Combined pSTAT5 / RELA ratio and total pSTAT5 levels correlate best 
with survival in patients with progenitor B-ALL.   
a, Survival of B-ALL patients stratified by pSTAT5 and pSTAT5 / RELA ratio.  p-values 
represent log-rank test for trend of medians.  b, Survival of B-ALL patients that were 
stratified based on pSTAT5 / RELA ratio alone: low or high.  c, Survival of B-ALL 
patients that were separated into two equal-sized groups based on low or high pSTAT5 
levels.  d, e, Survival of B-ALL patients that were stratified by separating them based on 
pSTAT5 / RELA ratio (low or high) and then further subdividing those groups based 
pSTAT5 levels (low or high).  p-values in panels b-e represent log-rank (Mantel-Cox) 
test. i, Statistical summary of the results shown in panels b-e.  
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Figure 2.17. STAT5 activation paired with deletion of IKAROS negatively correlates 
with the survival of BCR-ABL negative B-ALL patients.   
a, Survival of BCR-ABL negative B-ALL patients stratified by pSTAT5 and IKAROS 
status: WT or deleted (Δ). p-values represent log-rank test for trend of medians.  b, 
Survival of BCR-ABL negative B-ALL patients that were stratified based on IKAROS 
status alone: WT or deleted.  c, Survival of BCR-ABL negative B-ALL patients that were 
separated into two equal-sized groups based on low or high pSTAT5 levels.  d, e, 
Survival of BCR-ABL negative B-ALL patients that were stratified by separating them 
based on IKAROS status (WT or deleted) and then further subdividing those groups 
based pSTAT5 levels (low or high).  p-values in panels b-e represent log-rank (Mantel-
Cox) test. f, Statistical summary of the results shown in panels b-e.  ND = not done. 
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Figure 2.18. STAT5 activation paired with deletion of IKAROS negatively correlates 
with remission duration in BCR-ABL negative B-ALL patients.   
a, Remission duration in BCR-ABL negative B-ALL patients stratified by pSTAT5 and 
IKAROS status: WT or deleted (Δ). p-values represent log-rank test for trend of medians.  
b, Remission duration in BCR-ABL negative B-ALL patients that were stratified based on 
IKAROS status alone: WT or deleted.  c, Remission duration in BCR-ABL negative B-
ALL patients that were separated into two equal-sized groups based on low or high 
pSTAT5 levels.  d, e, Remission duration in BCR-ABL negative B-ALL patients that were 
stratified by separating them based on IKAROS status (WT or deleted) and then further 
subdividing those groups based pSTAT5 levels (low or high). p-values in panels b-e 
represent log-rank (Mantel-Cox) test. f, Statistical summary of the results shown in 
panels b-e.   	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Figure 2.19. Combined pSTAT5 / RELA ratio and total pSTAT5 levels correlate best 
with survival in patients with BCR-ABL negative progenitor B-ALL.   
a, Survival of BCR-ABL negative B-ALL patients stratified by pSTAT5 and pSTAT5 / 
RELA ratio.  p-values represent log-rank test for trend of medians.  b, Survival of BCR-
ABL negative B-ALL patients that were stratified based on pSTAT5 / RELA ratio alone: 
low or high.  c, Survival of BCR-ABL negative B-ALL patients that were separated into 
two equal-sized groups based on low or high pSTAT5 levels.  d, e, Survival of BCR-ABL 
negative B-ALL patients that were stratified by separating them based on pSTAT5 / 
RELA ratio (low or high) and then further subdividing those groups based pSTAT5 levels 
(low or high).  p-values in panels b-e represent log-rank (Mantel-Cox) test. i, Statistical 
summary of the results shown in panels b-e.  
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Discussion 
This research demonstrates that STAT5 activation cooperates with defects in a 
BLNK-BTK-PKCβ-NFκB pathway to initiate leukemia in progenitor B cells.  Contrary to 
previous reports, STAT5 did not promote leukemia by merely providing a survival or 
proliferation signal.  Instead, we found that STAT5 synergized with the loss of pre-BCR 
signaling components to modulate the expression of several NFκB target genes, 
including known oncogenes.  Therefore these data suggest that STAT5 antagonizes 
gene regulation by NFκB.  This interaction appears to be direct in many cases, as 
STAT5 was bound to roughly half of the NFκB target genes that were deregulated in the 
Stat5b-CA x Blnk+/-, Stat5b-CA x Xid and Stat5b-CA x Prkcb-/- leukemias.  In addition, we 
found that STAT5 binds to and represses the expression of Nfkb2.  Therefore, STAT5 
antagonizes the function of NFκB by multiple mechanisms.  Similarly, we found that 
STAT5 opposed gene regulation by IKAROS, which is positively regulated by the pre-
BCR and NFκB.  Moreover, STAT5 and IKAROS binding directly overlapped at 
hundreds of loci and luciferase studies suggested that these factors can compete for 
binding to target gene sequences.  STAT5 may also oppose the function of IKAROS by 
directly binding to and repressing the expression of Ikaros.  We also found that STAT5 
binding overlapped with the binding of the B cell transcription factors PAX5, EBF1, PU.1, 
IRF4, and IKAROS, particularly at B cell super-enhancers.  Moreover, those super-
enhancers with the highest STAT5 binding were associated with genes that regulate pre-
B cell survival, proliferation, and differentiation.  These data were recapitulated in 
humans, as STAT5 binding directly overlapped with NFκB and IKAROS at thousands of 
loci in a human B lymphoblastoid cell line.  Additionally, high levels of STAT5 binding in 
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the human B cell line tended to occur at super-enhancers that were associated with a 
similar regulatory gene network identified in mouse pre-B cells.  Finally, the ratio of 
active STAT5 to functional IKAROS alleles negatively correlated with the remission 
duration and survival of B-ALL patients.  Similarly, high levels of active STAT5 and a 
high ratio of active STAT5 to NFκB correlated with shorter overall survival of B-ALL 
patients.   
Our studies suggest a model in which the balance between STAT5 and a 
network of B cell transcription factors at super-enhancers acts as a molecular switch to 
govern appropriate progenitor B cell survival, proliferation and differentiation (Figures 
2.20, 2.21).  Altering the balance between these two antagonistic pathways drives B cell 
transformation, while the degree of imbalance underlies how B-ALL patients will respond 
to therapy (Figure 2.21).  Our findings suggest that strategies aimed at altering this 
balance, involving STAT5 inhibition paired with NFκB agonism, could potentially inhibit 
B-ALL in patients who are at high-risk of relapse. 
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Figure 2.20. STAT5 and a B cell transcriptional network regulate progenitor B cell 
survival, proliferation and differentiation.   
A model illustrating how the IL7R/STAT5 pathway and a B cell transcriptional network 
regulate progenitor B cell super-enhancer networks.  SE = super-enhancer. 
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Figure 2.21. The balance between STAT5 signals and a B cell transcriptional 
network govern appropriate progenitor B cell survival, proliferation and 
differentiation.   
A model illustrating how the balance between the IL7R/STAT5 pathway and the pre-
BCR and PAX5, EBF, PU.1, IRF4, and IKAROS (PEPII) transcriptional network govern 
progenitor B cell survival, proliferation, and differentiation. SE = super-enhancers. 
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Chapter 3:  Implications of the ratio of STAT5 to IKAROS or NFκB dictating patient 
outcomes 
Conclusions 
This work demostrates that STAT5 cooperates with defects in numerous pre-
BCR signaling components to initiate B-ALL.  Previous studies have suggested that the 
pre-BCR adaptor BLNK suppresses leukemia by binding to JAK3 and inhibiting JAK-
STAT5 signaling132.  However this is probably not the only way that BLNK suppress B-
ALL, as Stat5b-CA cooperates with deficiencies in signaling effectors downstream of 
Blnk such as Btk, Prkcb, and Nfkb1 to initiate B-ALL.  Instead, our results suggest that 
BLNK suppresses leukemia by activating a linear tumor suppressor pathway involving 
BLNK-BTK-PKCβ-NFκB-IRF4/8-IKAROS/AIOLOS, which inhibits cell cycle progression 
and promotes differentiation50,60,90,94,96,142,147–149,174,211–213,223,324–326.  
Our results also demonstrate that Nfkb1 acts as a tumor suppressor in pre-B 
cells.  This is a relatively unique role for NFκB in B cells, as NFκB activity usually 
promotes transformation in mature B cells142.  Recent studies support our findings, as 
Nfkb1 expression is decreased in B-ALL samples compared to healthy controls327.  
NFκB is likely acting as a tumor suppressor in pre-B cells because of contextual factors 
that influence the activity of NFκB224.  However, what these factors are in pre-B cells is 
unknown.  Our data suggests that one way that NFκB suppresses pre-B cell leukemia is 
by inducing the IRF4/8-IKAROS/AIOLOS pathway.  In addition, NFκB binding overlaps 
with STAT5 in human B lymphoblastoid cells, including at the oncogenes Bcl2l1, Myc, 
and Ccnd2.  Moreover, our STAT5 ChIP-seq dataset revealed that NFκB binding motifs 
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were enriched within 5 bp of STAT5 binding sites.  Furthermore, our microarray data 
indicates that STAT5 and NFκB antagonize target gene regulation by one another.  
Together these data suggest that NFκB could be competing with STAT5 for binding to 
shared target genes and preventing STAT5 from promoting a pro-leukemic gene 
program.  Conversely, NFκB may antagonize STAT5 gene regulation by non-
competitive mechanisms as well.  Therefore, our data suggest a multifaceted role for 
NFκB in suppressing STAT5-driven B-ALL. 
In mature B cells, on the other hand, NFκB activity promotes transformation.  In 
addition, a previous study suggested that STAT5 and NFκB cooperate to drive 
transformation in mature B cells328.  Moreover, we found that STAT5 and NFκB bind 
near one another in B lymphoblastoid cells.  Therefore, these data suggest that STAT5 
and NFκB may drive transformation in mature B cells by synergistically regulating 
oncogenes such as MYC, CCND2, and BCL2L1.   
Our microarray and ChIP-Seq data indicate that STAT5 and IKAROS are 
reciprocally regulating the expression of hundreds of shared target genes.  This could be 
by direct or indirect mechanisms.  Approximately half of the shared target genes showed 
direct binding overlap.  Moreover, our luciferase assays suggest that STAT5 and 
IKAROS binding overlaps at a sequence level and that these factors likely compete for 
binding.  However, STAT5 and IKAROS are likely antagonizing the function of one 
another by non-competitive mechanisms at other shared targets for which their binding 
does not overlap.  Instead, these transcription factors may opposingly open or close the 
chromatin by binding to different sites within shared target gene loci.  STAT5 can also 
oppose the function of IKAROS and NFκB by binding to and repressing the transcription 
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of Ikaros, Aiolos, Nfkb2, and potentially Nfkb1.  Therefore STAT5 can potentially 
antagonize IKAROS and NFκB activity by directly competing for binding to target genes, 
by opposing regulation of shared target genes via non-competitive binding, and by 
binding to and repressing the expression of Ikaros and Nfkb transcription factors.  
In addition, deletions of IKAROS may promote transformation by increasing 
STAT5 accessibility to target genes and enhancing responsiveness to STAT5 in 
leukemic cells that already have increased STAT5 activity.  Indeed, IKAROS deletions 
do not drive leukemia alone68,174 but do drive leukemia when paired with STAT5-
activating mutations, such as BCR-ABL174 or Stat5b-CA.  IKAROS also appears to inhibit 
the activation of STAT5, as dominant negative isoforms of IKAROS lead to an increase 
in STAT5 activity329.  This model of reciprocal antagonism between STAT5 and IKAROS 
is supported by multiple pieces of evidence.  IKAROS cooperates with IL7 withdrawal to 
promote cell cycle exit, pre-BCR down-regulation, and light chain expression68.  
Additionally, IKAROS deletions are strongly associated with mutations that promote 
STAT5 activation175,178. 
Similarly, abrogations in pre-BCR signlaing may increase sensitivity to IL7-
STAT5 signaling by decreasing NFκB and IKAROS activity.  This is supported by the 
observation that Blnk-/- and Plcg2-/- pre-B cells proliferate more than WT pre-B cells in 
response to IL7210,220.  Our model also suggests that one reason BCR-ABL+ leukemias 
select for pre-BCR signaling defects153,233 is to enhance responsiveness to STAT5.  
Moreover, our data predicts that defects in pre-BCR signaling components or IKAROS 
may cooperate with other STAT5 activating mutations involving JAK2, CRLF2, or IL7R to 
drive leukemogenesis.  This is supported by observations that IKAROS deletions are 
enriched in leukemias that also have translocations in JAK2 and/or CRLF29,177,178.  
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Therefore, deficiencies in IKAROS and/or pre-BCR signaling may promote B-ALL by 
increasing STAT5 accessibility to target genes and may cooperate with several STAT5-
activating mutations to initiate B-ALL.  
IKAROS is part of a large network of transcription factors that promote B cell 
development.  We found that STAT5 binding overlapped with many of these factors 
including PAX5, EBF1, PU.1, IRF4, and IKAROS.  However, it is currently unclear how 
these transcription factors are influencing the binding of one another or how these 
factors interact to affect gene expression.  IKAROS is known to compete with EBF1 for 
binding to the promoter of the pre-BCR component Igll1 (λ5)94,154.  At this locus, EBF1 
promotes expression whereas IKAROS inhibits expression.  Igll1 is upregulated in the 
Stat5b-CA x Blnk+/-, Stat5b-CA x Xid and Stat5b-CA x Prkcb-/- leukemias and STAT5 
directly binds to Igll1, suggesting that STAT5 directly upregulates Igll1.  We found similar 
evidence that STAT5 binds to and positively regulates another pre-BCR component, 
Vpreb1, which is also positively regulated by EBF1 and PAX5 but repressed by 
IKAROS75,87,96,187.  However, our data also indicates that STAT5 opposes regulation by 
EBF1 and PAX5 at other loci such at Irf4, Aiolos, and Bcl669,87.  This suggests a more 
complex model whereby STAT5 synergizes with EBF1 and PAX5 in the early stages of 
B cell development to antagonize gene regulation by IKAROS.  However, at later stages 
of B cell development STAT5 opposes gene regulation by EBF1, PAX5, and IKAROS.   
Even though STAT5 can oppose and cooperate with EBF1 and PAX5 to 
modulate target gene expression, it seems that the antagonism between the pathways 
dictates the outcome of B-ALL.  This is supported by the observation that Pax5-/- 
progenitor B cells proliferate more than WT controls in response to IL786.  This suggests 
that PAX5 suppresses IL7-driven proliferation, which is mediated in part by STAT5128,330.  
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Moreover, PAX5 and EBF1 suppress STAT5-driven leukemia, as Pax5 or Ebf1 
heterozygousity cooperates with STAT5 activation to drive B-ALL-like leukemia in mice2. 
Therefore, deficiencies in pre-BCR signaling or in the B cell transcriptional network 
increase sensitivity to IL7-STAT5 signaling, potentially by preventing IKAROS, NFκB, 
PAX5, and/or EBF1 from antagonizing gene regulation by STAT5. 
 Another unanswered question worth investigating is how do STAT5 and PEPII 
factors interact at target loci temporally.  For example, IKAROS, EBF1 and STAT5 are 
expressed earlier in B cell development than PAX5.  Moreover, STAT5 activation peaks 
in pro-B cells, whereas IKAROS, EBF1 and PAX5 levels continue to rise as cells 
differentiate into mature B cells.  In addition, NFκB, IRF4, IRF8, IKAROS and AIOLOS 
are all induced by pre-BCR signaling.  STAT5 may occupy shared target genes in pro-B 
cells, but then active STAT5 levels decrease in pre-B cells, thereby allowing PEPII 
factors to occupy such sites.  Additionally, PAX5 and EBF1 binding redistributes to 
different loci as progenitors progress throughout B cell development30,312.  The factors 
that guide or prevent this redistribution have not been identified.  However, it seems 
likely that NFκB, IRF4, IRF8, IKAROS, and AIOLOS may guide the binding of EBF1 and 
PAX5 to new sites following pre-BCR signaling.  It is also tempting to speculate that 
STAT5 binding to shared target genes could physically prevent EBF1 and PAX5 from 
redistributing to new sites in the genome.  The redistribution of EBF1 and PAX5 is likely 
important in the differentiation of B cells and potentially in B-ALL.  However, this has yet 
to be studied.   
We observed extensive overlap between STAT5 and PEPII factors particularly at 
super-enhancers.  In addition, we found significant overlap of STAT5 and 4 or more 
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PEPII factors at hundreds of loci outside of super-enhancers.  These sites could be 
important in the regulation of genes that control B cell differentiation and leukemia.  
However, what these sites are doing in normal B cell development or transformation 
remains unclear.  Super-enhancers are defined by high levels of the coactivators 
Mediator or the open chromatin mark H3K27Ac and are usually associated with those 
genes that are expressed at the highest levels.  Therefore, the overlap of PEPII factors 
outside of super-enhancers may correspond to loci that are not expressed at high levels 
in normal B cell progenitors, but are still important in transformation.  Studying these 
sites in further detail may provide valuable insights into the mechanisms underlying 
normal B cell development as well as the transformation of B cell progenitors.   
 One caveat to our STAT5 ChIP-seq data is that it was done in Stat5b-CA x 
Blnk+/- leukemias, which have hyperactive levels of STAT5.  Therefore, is this the reason 
that we observed such a large overlap in binding between STAT5 and PEPII factors?  
Potentially STAT5 binding would not normally be bound to such sites in WT pre-B cells.  
However, we know that in WT pre-B cells, STAT5 is bound to Ikaros, which was one of 
the weakest STAT5 binding sites that we observed in the leukemias (Figure 2.10b).  
Therefore, this suggests that STAT5 may occupy many of the same sites in WT pre-B 
cells, however, the amount of STAT5 bound at those sites may be lower in WT cells.  
Therefore, a comparison of STAT5 binding in WT pre-B cells and transformed pre-B 
cells should be done to test this possibility.  Moreover, it may also be insightful to test 
how STAT5 binding changes in the absence of other transcription factors such as 
IKAROS, NFκB, PAX5, EBF1, or IRF4.  Also, how does the binding of these factors 
change in response to more or less active STAT5.  This would shed light on whether 
these factors cooperate or compete for binding to sites of overlap.  Moreover, 
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determining how the binding of these transcription factors changes in B-ALL may help to 
explain why these factors are commonly deregulated in B-ALL.  
Several other questions remain in regards to the interaction between STAT5 and 
PEPII transcription factors.  What is happening at sites of STAT5 and PEPII factor 
binding overlap?  Can STAT5 and PEPII factors compete for binding to shared target 
genes and/or synergistically bind to other loci?  Do STAT5 and PEPII factors interact 
directly by protein-protein interactions or via co-repressors or co-activators functioning 
as adaptors?  Such interactions are possible since both STAT5 and IKAROS have been 
shown to bind to the co-repressor SMRT125,331.  In addition, how does the interaction of 
STAT5 and PEPII factors at shared sites affect gene transcription?  What determines 
whether the binding of these factors turns on or off target gene expression?  For 
example, the mechanism by which STAT5 modulates gene expression is uncertain.  
STAT5 can interact with other co-regulators besides SMRT such as the co-activator 
p300332,333.  However, the mechanisms that determine whether STAT5 interacts with a 
co-activator or a co-repressor to promote or repress transcription are poorly understood.  
One mechanism may involve the interaction of STAT5 with PEPII factors.  Finally, which 
co-regulators STAT5 is interacting with to drive B-ALL is also unknown.  
In this study, we identified groups of B-ALL patients that are at high-risk of 
relapse and death.  Moreover, our data suggests that the combination of active STAT5 
levels and deleted IKAROS or active STAT5 and the ratio of active STAT5 to RELA 
could be used as prognostic indicators to better stratify B-ALL patients.  These markers 
could potentially be used with current risk stratification methods6,9 such as age and white 
blood cell counts to further improve stratification.  This method could potentially be used 
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to aggressively treat those patients that we have identified as high-risk, and minimize the 
over-treatment of patients that will not benefit from harsh treatment regimens.   
Moreover, our data could be used to develop more tailored therapies that treat 
patients based on the specific underlying causes of disease.  For example, those 
patients with IKAROS deletions could be treated with NFκB agonists to restore IKAROS 
expression.  Additionally, induction of NFκB, IRF4, IRF8, and/or AIOLOS by NFκB 
agonists may compensate in cases where both alleles of IKAROS are deleted.  
Moreover, NFκB agonists may synergize with SYK agonists to further increase 
treatment efficacy.  IKAROS and SYK positively regulate one another68,94,152,153,188,334, 
which potentially forms a positive feedback loop.  Evidence for the synergy between 
SYK and IKAROS lies in the observation that patients with forms of B-ALL that do not 
express µH chain or IKAROS have poorer survival than those with leukemia that only 
express one of these proteins169,170.  Increasing SYK activity has already proven to 
induce cell death in BCR-ABL+ B-ALL233.  Therefore, combining the use of NFκB 
agonists with SYK agonists may induce the activity of IKAROS more than using either 
agonist alone.   
Other factors that are also likely involved in a positive feedback loop with SYK 
and IKAROS include BLNK, FOXO1, NFκB, IRF4, PAX5, and EBF1 (Figure 3.1).  
Therefore, loss of one or two members of this network may reduce the expression of all 
members in this network.  Additionally, because super-enhancers are known to be 
exquisitely sensitive to disturbances in transcriptional networks234,235, loss of one or two 
members in the B cell transcriptional network may disrupt the binding of several 
members of the network at super-enhancers.  This is supported by evidence that 
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deletion of EBF or E2A significantly affects PU.1 binding and distribution.  Likewise, 
EBF1 binding is severely impaired in E2A deficient B cell progenitors69,80.  Therefore B 
cell transcription factors affect the binding and distribution of other B cell transcription 
factors.  Therefore, disturbances in the B cell transcriptional network may 
disproportionately affect the expression of genes associated with B cell super-
enhancers, which are known to be key in the development of B-ALL.  Therefore, 
treatments aimed at restoring this super-enhancer network may be very effective in 
treating patients that have deletions in the transcription factors that make up this 
network.  Therefore, SYK and NFκB agonists may be effective in treating patients with 
PAX5 or EBF1 deletions, for example, in addition to those with IKAROS deletions or 
decreased expression of pre-BCR signaling components. 
For those B-ALL cases with high STAT5 levels, then our data suggests that 
STAT5 inhibitors should be employed as treatment options.  Our data also suggests that 
the ratio of STAT5 to IKAROS or NFκB is important in B-ALL.  Therefore, combining the 
treatment of STAT5 inhibitors along with NFκB and SYK agonists may be effective in B-
ALL cases with high levels of active STAT5 or deleted IKAROS in addition to those that 
have both pathways deregulated.  Moreover, the levels of STAT5, NFκB, and SYK may 
only need to be moderately modulated in order to effectively treat B-ALL.  This would 
minimize off target effects to other STAT5, NFκB and SYK dependent processes. 
Therefore, moderate STAT5 inhibition combined with moderate agonsim of NFκB and 
SYK may effectively treat high-risk cases of B-ALL such as BCR-ABL+ and BCR-ABL-
like leukemia.  
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In conclusion, these studies have provided many insights and potential 
mechanisms by which STAT5 activation cooperates with defects in pre-BCR signaling 
components and B cell transcription factors to initiate B-ALL.  Moreover, this work can 
potentially be used to develop novel risk stratification methods and treatment options to 
more specifically and effectively treat B-ALL.  Finally, this research suggests new 
directions for scientific inquiry to further elucidate the underlying causes of B-ALL and 
ultimately cure B-ALL. 
IKAROS, FOXOs, EBF1, PAX5, and IRF4 form a self-reinforcing transcriptional network 
in B cell progenitors.  This network of transcription factors positively regulates pre-BCR 
signaling components such a SYK and BLNK, which feedback to positively regulate the 
factors in the B cell transcriptional network.  
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Figure 3.1. SYK and IKAROS form a positive feedback loop with other factors that 
regulate B cell development.  
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